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Foreword
In 2008, WHO launched the mental health Gap Action 
Programme (mhGAP) to address the lack of care, especially in 
low- and middle-income countries, for people suffering from 
mental, neurological, and substance use disorders. Fourteen 
per cent of the global burden of disease is attributable to these 
disorders and almost three quarters of this burden occurs in 
low- and middle-income countries. The resources available in 
countries are insuffi cient – the vast majority of countries allocate 
less than 2% of their health budgets to mental health leading 
to a treatment gap of more than 75% in many low- and middle-
income countries.
Taking action makes good economic sense. Mental, neurological 
and substance use disorders interfere, in substantial ways, 
with the ability of children to learn and the ability of adults to 
function in families, at work, and in society at large. Taking 
action is also a pro-poor strategy. These disorders are risk 
factors for, or consequences of, many other health problems, 
and are too often associated with poverty, marginalization and 
social disadvantage.
There is a widely shared but mistaken idea that improvements in 
mental health require sophisticated and expensive technologies 
and highly specialized staff. The reality is that most of the 
mental, neurological and substance use conditions that result in 
high morbidity and mortality can be managed by non-specialist 
health-care providers. What is required is increasing the capacity 
of the primary health care system for delivery of an integrated 
package of care by training, support and supervision. 
It is against this background that I am pleased to present 
“mhGAP Intervention Guide for mental, neurological and 
substance use disorders in non-specialized health settings” as 
a technical tool for implementation of the mhGAP Programme. 
The Intervention Guide has been developed through a 
systematic review of evidence, followed by an international 
consultative and participatory process. It provides the full range 
of recommendations to facilitate high quality care at fi rst- and 
second-level facilities by the non-specialist health-care providers 
in resource-poor settings. It presents integrated management of 
priority conditions using protocols for clinical decision-making. 
I hope that the guide will be helpful for health-care providers, 
decision-makers, and programme managers in meeting the 
needs of people with mental, neurological and substance use 
disorders. 
We have the knowledge. Our major challenge now is to translate 
this into action and to reach those people who are most in need.
Dr Margaret Chan
Director-General
World Health Organization
Health systems around the world face enormous 
challenges in delivering care and protecting the 
human rights of people with mental, neurological 
and substance use disorders. The resources available 
are insufﬁ cient, inequitably distributed and 
inefﬁ ciently used. As a result, a large majority of 
people with these disorders receive no care at all.
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Introduction
Mental Health Gap Action Programme  
(mhGAP) – background
About four out of five people in low- and middle-income 
countries who need services for mental, neurological and 
substance use conditions do not receive them. Even when 
available, the interventions often are neither evidence-based nor 
of high quality. WHO recently launched the mental health Gap 
Action Programme (mhGAP) for low- and middle-income countries 
with the objective of scaling up care for mental, neurological and 
substance use disorders. This mhGAP Intervention Guide 
(mhGAP-IG) has been developed to facilitate mhGAP-related 
delivery of evidence-based interventions in non-specialized 
health-care settings.
There is a widely shared but mistaken idea that all mental health 
interventions are sophisticated and can only be delivered by 
highly specialized staff. Research in recent years has demonstrated 
the feasibility of delivery of pharmacological and psychosocial 
interventions in non-specialized health-care settings. The present 
model guide is based on a review of all the science available in 
this area and presents the interventions recommended for use in 
low- and middle-income countries. The mhGAP-IG includes 
guidance on evidence-based interventions to identify and 
manage a number of priority conditions. The priority conditions 
included are depression, psychosis, bipolar disorders, epilepsy, 
developmental and behavioural disorders in children and 
adolescents, dementia, alcohol use disorders, drug use disorders, 
self-harm / suicide and other significant emotional or medically 
unexplained complaints. These priority conditions were selected 
because they represent a large burden in terms of mortality, 
morbidity or disability, have high economic costs, and are 
associated with violations of human rights. 
Development of the mhGAP  
Intervention Guide (mhGAP-IG)
The mhGAP-IG has been developed through an intensive process 
of evidence review. Systematic reviews were conducted to develop 
evidence-based recommendations. The process involved a WHO 
Guideline Development Group of international experts, who 
collaborated closely with the WHO Secretariat. The recommendations 
were then converted into clearly presented stepwise interventions, 
again with the collaboration of an international group of experts. 
The mhGAP-IG was then circulated among a wider range of 
reviewers across the world to include all the diverse contributions.
The mhGAP-IG is based on the mhGAP Guidelines on interventions 
for mental, neurological and substance use disorders (http://
www.who.int/mental_health/mhgap/evidence/en/). The mhGAP 
Guidelines and the mhGAP-IG will be reviewed and updated in 5 
years. Any revision and update before that will be made to the 
online version of the document.
Purpose of the mhGAP Intervention Guide
The mhGAP-IG has been developed for use in non-specialized 
health-care settings. It is aimed at health-care providers working 
at first- and second-level facilities. These health-care providers 
may be working in a health centre or as part of the clinical team 
at a district-level hospital or clinic. They include general physicians, 
family physicians, nurses and clinical officers. Other non-specialist 
health-care providers can use the mhGAP-IG with necessary 
adaptation. The first-level facilities include the health-care centres 
that serve as first point of contact with a health professional and 
provide outpatient medical and nursing care. Services are provided 
by general practitioners or physicians, dentists, clinical officers, 
community nurses, pharmacists and midwives, among others. 
Second-level facilities include the hospital at the first referral level 
responsible for a district or a defined geographical area containing 
a defined population and governed by a politico-administrative 
organization, such as a district health management team. The 
district clinician or mental health specialist supports the first- 
level health-care team for mentoring and referral.
The mhGAP-IG is brief so as to facilitate interventions by busy 
non-specialists in low- and middle-income countries. It describes 
in detail what to do but does not go into descriptions of how to 
do. It is important that the non-specialist health-care providers 
are trained and then supervised and supported in using the 
mhGAP-IG in assessing and managing people with mental, 
neurological and substance use disorders. 
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It is not the intention of the mhGAP-IG to cover service 
development. WHO has existing documents that guide service 
development. These include a tool to assess mental health 
systems, a Mental Health Policy and Services Guidance Package, 
and specifi c material on integration of mental health into 
primary care. Information on mhGAP implementation is provided 
in mental health Gap Action Programme: Scaling up care for 
mental, neurological and substance use disorders. Useful WHO 
documents and their website links are given at the end of the 
introduction. 
Although the mhGAP-IG is to be implemented primarily by 
non-specialists, specialists may also fi nd it useful in their work. 
In addition, specialists have an essential and substantial role 
in training, support and supervision. The mhGAP-IG indicates 
where access to specialists is required for consultation or 
referral. Creative solutions need to be found when specialists are 
not available in the district. For example, if resources are scarce, 
additional mental health training for non-specialist health-care 
providers may be organized, so that they can perform some 
of these functions in the absence of specialists. Specialists 
would also benefi t from training on public health aspects of the 
programme and service organization. Implementation of the 
mhGAP-IG ideally requires coordinated action by public health 
experts and managers, and dedicated specialists with a public 
health orientation.
Adaptation of the mhGAP-IG 
The mhGAP-IG is a model guide and it is essential that it is 
adapted to national and local situations. Users may select 
a subset of the priority conditions or interventions to adapt 
and implement, depending on the contextual differences in 
prevalence and availability of resources. Adaptation is necessary 
to ensure that the conditions that contribute most to burden 
in a specifi c country are covered and that the mhGAP-IG is 
appropriate for the local conditions that affect the care of 
people with mental, neurological and substance use disorders in 
the health facility. The adaptation process should be used as an 
opportunity to develop a consensus on technical issues across 
disease conditions; this requires involvement of key national 
stakeholders. Adaptation will include language translation 
and ensuring that the interventions are acceptable in the 
sociocultural context and suitable for the local health system. 
mhGAP implementation – key issues
Implementation at the country level should start from 
organizing a national stakeholder’s meeting, needs 
assessment and identifi cation of barriers to scaling-up. 
This should lead to preparing an action plan for scaling up, 
advocacy, human resources development and task shifting 
of human resources, fi nancing and budgeting issues, 
information system development for the priority conditions, 
and monitoring and evaluation. 
District-level implementation will be much easier after 
national-level decisions have been put into operation. A 
series of coordination meetings is initially required at the 
district level. All district health offi cers need to be briefed, 
especially if mental health is a new area to be integrated 
into their responsibilities. Presenting the mhGAP-IG could 
make them feel more comfortable when they learn that it is 
simple, applicable to their context, and could be integrated 
within the health system. Capacity building for mental 
health care requires initial training and continued support 
and supervision. However, training for delivery of the 
mhGAP-IG should be coordinated in such a way as not to 
interrupt ongoing service delivery.
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How to use the mhGAP-IG
»  The mhGAP-IG starts with “General Principles of Care”. It 
provides good clinical practices for the interactions of health-
care providers with people seeking mental health care. All 
users of the mhGAP-IG should familiarize themselves with 
these principles and should follow them as far as possible.
»  The mhGAP-IG includes a “Master Chart”, which provides 
information on common presentations of the priority 
conditions. This should guide the clinician to the relevant 
modules.
 –  In the event of potential co-morbidity (two disorders 
present at the same time), it is important for the 
clinician to confirm the co-morbidity and then make an 
overall management plan for treatment.
 –  The most serious conditions should be managed first. 
Follow-up at next visit should include checking whether 
symptoms or signs indicating the presence of any other 
priority condition have also improved. If the condition 
is flagged as an emergency, it needs to be managed 
first. For example, if the person is convulsing, the acute 
episode should be managed first before taking detailed 
history about the presence of epilepsy.
»  The modules, organized by individual priority conditions, are 
a tool for clinical decision-making and management. Each 
module is in a different colour to allow easy differentiation. 
There is an introduction at the beginning of each module that 
explains which condition(s) the module covers. 
»  Each of the modules consists of two sections. The first section is 
the assessment and management section. In this section, 
the contents are presented in a framework of flowcharts with 
multiple decision points. Each decision point is identified by a 
number and is in the form of a question. Each decision point 
has information organized in the form of three columns – 
“assess, decide and manage”. 
 
ManageAssess Decide
 –  The left-hand column includes the details for assessment 
of the person. It is the assess column, which guides 
users how to assess the clinical condition of a person. 
Users need to consider all elements of this column before 
moving to the next column.
 –  The middle column specifies the different scenarios the 
health-care provider might be facing. This is the decide 
column. 
 –  The right-hand column describes suggestions on how 
to manage the problem. It is the manage column. It 
provides information and advice, related to particular 
decision points, on psychosocial and pharmacological 
interventions. The management advice is linked (cross-
referenced) to relevant intervention details that are too 
detailed to be included in the flowcharts. The relevant 
intervention details are identified with codes. For example, 
DEP 3 means the intervention detail number three for the 
Moderate-Severe Depression Module. 
 –  The mhGAP-IG uses a series of symbols to highlight 
certain aspects within the assess, decide and manage 
columns of the flowcharts. A list of the symbols and their 
explanation is given in the section Abbreviations and 
Symbols.
Introduction
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MANAGE
MOVE TO NEXT
CONTINUE AS ABOVE…
EXIT
or
SPECIFIC INSTRUCTIONS
ASSESS
ASSESS
DECIDE
DECIDE
Instructions to use fl owcharts correctly and comprehensively
»  The second section of each module consists of intervention 
details which provides more information on follow-up, 
referral, relapse prevention, and more technical details of 
psychosocial / non-pharmacological  and pharmacological 
treatments, and important side-effects or interactions. The 
intervention details are presented in a generic format. They 
will require adaptation to local conditions and language, and 
possibly addition of examples and illustrations to enhance 
understanding, acceptability and attractiveness.
»  Although the mhGAP-IG is primarily focusing on clinical 
interventions and treatment, there are opportunities for the 
health-care providers to provide evidence-based interventions 
to prevent mental, neurological and substance use disorders 
in the community. Prevention boxes for these interventions 
can be found at the end of some of the conditions.
»  Section V covers “Advanced Psychosocial Interventions” 
For the purposes of the mhGAP-IG, the term “advanced 
psychosocial interventions” refers to interventions that take 
more than a few hours of a health-care provider’s time to 
learn and typically more than a few hours to implement. 
Such interventions can be implemented in non-specialized 
care settings but only when suffi cient human resource time 
is made available. Within the fl owcharts in the modules, such 
interventions are marked by the abbreviation INT indicating 
that these require a relatively more intensive use of human 
resources.
Introduction
NOTE: Users of the mhGAP-IG need to start at the top 
of the assessment and management section and move 
through all the decision points to develop a comprehensive 
management plan for the person.
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Assessment of iodine deficiency disorders and monitoring 
their elimination: A guide for programme managers. Third 
edition (updated 1st September 2008)
http://www.who.int/nutrition/publications/micronutrients/ 
iodine_deficiency/9789241595827/en/index.html
CBR: A strategy for rehabilitation, equalization of 
opportunities, poverty reduction and social inclusion of 
people with disabilities (Joint Position Paper 2004) 
http://whqlibdoc.who.int/publications/2004/9241592389_eng.pdf
Clinical management of acute pesticide intoxication:  
Prevention of suicidal behaviours 
http://www.who.int/mental_health/prevention/suicide/ 
pesticides_intoxication.pdf
Epilepsy: A manual for medical and clinical officers in Africa
http://www.who.int/mental_health/media/en/639.pdf
IASC guidelines on mental health and psychosocial  
support in emergency settings 
http://www.who.int/mental_health/emergencies/guidelines_
iasc_mental_health_psychosocial_april_2008.pdf
IMCI care for development: For the healthy growth and 
development of children
http://www.who.int/child_adolescent_health/documents/
imci_care_for_development/en/index.html
Improving health systems and services for mental health 
http://www.who.int/mental_health/policy/services/mhsystems/
en/index.html
Infant and young child feeding – tools and materials 
http://www.who.int/child_adolescent_health/documents/ 
iycf_brochure/en/index.html
Integrated management of adolescent and adult illness / 
Integrated management of childhood illness (IMAI/IMCI) 
http://www.who.int/hiv/topics/capacity/en/
Integrated management of childhood illness (IMCI) 
http://www.who.int/child_adolescent_health/topics/ 
prevention_care/child/imci/en/index.html
Integrating mental health into primary care – a global  
perspective 
http://www.who.int/mental_health/policy/ 
Integratingmhintoprimarycare2008_lastversion.pdf
Lancet series on global mental health 2007  
http://www.who.int/mental_health/en/
Mental health Gap Action Programme (mhGAP)  
http://www.who.int/mental_health/mhGAP/en/
mhGAP Evidence Resource Centre  
http://www.who.int /mental_health/mhgap/evidence/en/
Pharmacological treatment of mental disorders in primary 
health care 
http://www.who.int/mental_health/management/psychotropic/
en/index.html
Pregnancy, childbirth, postpartum and newborn care:  
A guide for essential practice 
http://www.who.int/making_pregnancy_safer/documents/ 
924159084x/en/index.html
Preventing suicide: a resource series 
http://www.who.int/mental_health/resources/preventingsuicide/
en/index.html
Prevention of cardiovascular disease: guidelines for  
assessment and management of cardiovascular risk  
http://www.who.int/cardiovascular_diseases/guidelines/ 
Prevention_of_Cardiovascular_Disease/en/index.html
Prevention of mental disorders: Effective interventions 
and policy options 
http://www.who.int/mental_health/evidence/en/prevention_of_
mental_disorders_sr.pdf
Promoting mental health: Concepts, emerging evidence, 
practice 
http://www.who.int/mental_health/evidence/MH_Promotion_
Book.pdf
World Health Organization Assessment Instrument for 
Mental Health Systems (WHO-AIMS) 
http://www.who.int/mental_health/evidence/WHO-AIMS/en/
Introduction
Related WHO documents that can be downloaded from the following links:
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General Principles of Care GPC
Health-care providers should follow good clinical practices in 
their interactions with all people seeking care. They should respect 
the privacy of people seeking care for mental, neurological and 
substance use disorders, foster good relationships with them 
and their carers, and respond to those seeking care in a non-
judgmental, non-stigmatizing and supportive manner. The 
following key actions should be considered when implementing 
the mhGAP Intervention Guide. These are not repeated in each 
module.
wire possition
General Principles of Care GPC
1.  Communication with people seeking care 
and their carers 
»  Ensure that communication is clear, empathic, and sensitive to 
age, gender, culture and language differences. 
»  Be friendly, respectful and non-judgmental at all times.
»  Use simple and clear language.
»  Respond to the disclosure of private and distressing 
information (e.g. regarding sexual assault or self-harm) with 
sensitivity.
»  Provide information to the person on their health status in 
terms that they can understand. 
»  Ask the person for their own understanding of the condition.
2.  Assessment
»  Take a medical history, history of the presenting complaint(s), 
past history and family history, as relevant. 
»  Perform a general physical assessment.
»  Assess, manage or refer, as appropriate, for any concurrent 
medical conditions.
»  Assess for psychosocial problems, noting the past and 
ongoing social and relationship issues, living and financial 
circumstances, and any other ongoing stressful life events.
3.  Treatment and monitoring
»  Determine the importance of the treatment to the person as 
well as their readiness to participate in their care.
»  Determine the goals for treatment for the affected person 
and create a management plan that respects their preferences 
for care (also those of their carer, if appropriate).
»  Devise a plan for treatment continuation and follow-up, in 
consultation with the person.
»  Inform the person of the expected duration of treatment, 
potential side-effects of the intervention, any alternative 
treatment options, the importance of adherence to the 
treatment plan, and of the likely prognosis.
»  Address the person’s questions and concerns about 
treatment, and communicate realistic hope for better 
functioning and recovery.
»  Continually monitor for treatment effects and outcomes, 
drug interactions (including with alcohol, over-the-counter 
medication and complementary/traditional medicines), and 
adverse effects from treatment, and adjust accordingly.
»  Facilitate referral to specialists, where available and as 
required.
»  Make efforts to link the person to community support.
»  At follow-up, reassess the person’s expectations of treatment, 
clinical status, understanding of treatment and adherence to 
the treatment and correct any misconceptions.
»  Encourage self-monitoring of symptoms and explain when to 
seek care immediately.
»  Document key aspects of interactions with the person and 
the family in the case notes.
»  Use family and community resources to contact people who 
have not returned for regular follow-up.
»  Request more frequent follow-up visits for pregnant women 
or women who are planning a pregnancy.
»  Assess potential risks of medications on the fetus or baby 
when providing care to a pregnant or breastfeeding woman.
»  Make sure that the babies of women on medications who 
are breastfeeding are monitored for adverse effects or 
withdrawal and have comprehensive examinations if required.
»  Request more frequent follow-up visits for older people 
with priority conditions, and associated autonomy loss or in 
situation of social isolation.
»  Ensure that people are treated in a holistic manner, meeting 
the mental health needs of people with physical disorders, 
as well as the physical health needs of people with mental 
disorders.
4.  Mobilizing and providing social support
»  Be sensitive to social challenges that the person may face, 
and note how these may influence the physical and mental 
health and well-being.
mhGAP-IG » General Principles of Care 6
General Principles of Care GPC
»  Where appropriate, involve the carer or family member in the 
person’s care.
»  Encourage involvement in self-help and family support 
groups, where available.
»  Identify and mobilize possible sources of social and 
community support in the local area, including educational, 
housing and vocational supports. 
»  For children and adolescents, coordinate with schools to 
mobilize educational and social support, where possible. 
5.  Protection of human rights
»  Pay special attention to national and international human 
rights standards (Box 1).
»  Promote autonomy and independent living in the community 
and discourage institutionalization.
»  Provide care in a way that respects the dignity of the person, 
that is culturally sensitive and appropriate, and that is free from 
discrimination on the basis of race, colour, sex, language, 
religion, political or other opinion, national, ethnic, indigenous 
or social origin, property, birth, age or other status. 
»  Ensure that the person understands the proposed treatment 
and provides free and informed consent to treatment. 
»  Involve children and adolescents in treatment decisions in a 
manner consistent with their evolving capacities, and give 
them the opportunity to discuss their concerns in private.
»  Pay special attention to confidentiality, as well as the right of 
the person to privacy. 
»  With the consent of the person, keep carers informed about 
the person’s health status, including issues related to 
assessment, treatment, follow-up, and any potential side-
effects.
»  Prevent stigma, marginalization and discrimination, and 
promote the social inclusion of people with mental, 
neurological and substance use disorders by fostering strong 
links with the employment, education, social (including 
housing) and other relevant sectors.
6.  Attention to overall well-being
»  Provide advice about physical activity and healthy body 
weight maintenance. 
»  Educate people about harmful alcohol use.
»  Encourage cessation of tobacco and substance use.
»  Provide education about other risky behaviour (e.g. unprotected 
sex).
»  Conduct regular physical health checks.
»  Prepare people for developmental life changes, such as 
puberty and menopause, and provide the necessary support.
»  Discuss plans for pregnancy and contraception methods with 
women of childbearing age. 
BOX 1  
Key international human rights standards
Convention against torture and other cruel, inhuman 
or degrading treatment or punishment. United Nations 
General Assembly Resolution 39/46, annex, 39 UN GAOR 
Supp. (No. 51) at 197, UN Doc. A/39/51 (1984). Entered 
into force 26 June 1987. 
http://www2.ohchr.org/english/law/cat.htm 
Convention on the elimination of all forms of discrimina-
tion against women (1979). Adopted by United Nations 
General Assembly Resolution 34/180 of 18 December 1979. 
http://www.un.org/womenwatch/daw/cedaw/cedaw.htm
Convention on the rights of persons with disabilities and 
optional protocol. Adopted by the United Nations General 
Assembly on 13 December 2006.  
http://www.un.org/disabilities/documents/convention/ 
convoptprot-e.pdf
Convention on the rights of the child (1989). Adopted by 
United Nations General Assembly Resolution 44/25 of 20 
November 1989. http://www2.ohchr.org/english/law/crc.htm 
International covenant on civil and political rights (1966). 
Adopted by UN General Assembly Resolution 2200A (XXI) 
of 16 December 1966.
http://www2.ohchr.org/english/law/ccpr.htm
International covenant on economic, social and cultural 
rights (1966). Adopted by UN General Assembly Resolu-
tion 2200A (XXI) of 16 December 1966.
http://www2.ohchr.org/english/law/cescr.htm
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mhGAP-IG Master Chart: Which priority condition(s) should be assessed?
1. These common presentations indicate the need for assessment. 
2. If people present with features from more than one condition, then all relevant conditions need to be assessed. 
3. All conditions apply to all ages, unless otherwise specified. 
COMMON PRESENTATION
CONDITION TO  
BE ASSESSED GO TO
10
18
32
40
O  Low energy; fatigue; sleep or appetite problems
O  Persistent sad or anxious mood; irritability
O  Low interest or pleasure in activities that used to be interesting or enjoyable 
O  Multiple symptoms with no clear physical cause (e.g. aches and pains, palpitations, numbness)
O  Difficulties in carrying out usual work, school, domestic or social activities
O  Abnormal or disorganized behaviour (e.g. incoherent or irrelevant speech, unusual appearance,  
self-neglect, unkempt appearance)
O  Delusions (a false firmly held belief or suspicion)
O  Hallucinations (hearing voices or seeing things that are not there)
O  Neglecting usual responsibilities related to work, school, domestic or social activities 
O  Manic symptoms (several days of being abnormally happy, too energetic, too talkative, very  
irritable, not sleeping, reckless behaviour)
O  Convulsive movement or fits / seizures
O  During the convulsion:  
– loss of consciousness or impaired consciousness  
– stiffness, rigidity  
– tongue bite, injury, incontinence of urine or faeces
O  After the convulsion: fatigue, drowsiness, sleepiness, confusion, abnormal behaviour,  
headache, muscle aches, or weakness on one side of the body
O  Delayed development: much slower learning than other children of same age in activities  
such as: smiling, sitting, standing, walking, talking / communicating and other areas of  
development, such as reading and writing 
O  Abnormalities in communication; restricted, repetitive behaviour
O  Difficulties in carrying out everyday activities normal for that age
Depression * o DEP
Psychosis * PSY
Epilepsy /  
Seizures
EPI
Developmental 
Disorders
DEV
Children and adolescents
wire possition
O  Excessive inattention and absent-mindedness, repeatedly stopping tasks before completion  
and switching to other activities 
O  Excessive over-activity: excessive running around, extreme difficulties remaining seated,  
excessive talking or fidgeting
O  Excessive impulsivity: frequently doing things without forethought
O  Repeated and continued behaviour that disturbs others (e.g. unusually frequent and severe  
temper tantrums, cruel behaviour, persistent and severe disobedience, stealing) 
O  Sudden changes in behaviour or peer relations, including withdrawal and anger
O  Decline or problems with memory (severe forgetfulness) and  
orientation (awareness of time, place and person)
O  Mood or behavioural problems such as apathy (appearing uninterested) or irritability 
O  Loss of emotional control – easily upset, irritable or tearful
O  Difficulties in carrying out usual work, domestic or social activities
O  Appearing to be under the influence of alcohol (e.g. smell of alcohol, looks intoxicated, hangover) 
O  Presenting with an injury
O  Somatic symptoms associated with alcohol use (e.g. insomnia, fatigue, anorexia, nausea,  
vomiting, indigestion, diarrhoea, headaches)
O  Difficulties in carrying out usual work, school, domestic or social activities
O  Appearing drug-affected (e.g. low energy, agitated, fidgeting, slurred speech)
O  Signs of drug use (injection marks, skin infection, unkempt appearance)
O  Requesting prescriptions for sedative medication (sleeping tablets, opioids)
O  Financial difficulties or crime-related legal problems 
O  Difficulties in carrying out usual work, domestic or social activities
O  Current thoughts, plan or act of self-harm or suicide 
O History of thoughts, plan or act of self-harm or suicide
Behavioural  
Disorders
Dementia
Alcohol Use 
Disorders
Drug Use  
Disorders
Self-harm /  
Suicide
44
50
58
66
74
* The Bipolar Disorder (BPD) module is accessed through either the Psychosis module or the Depression module. 
o The Other Significant Emotional or Medically Unexplained Complaints (OTH) module is accessed through the Depression module.
Older people
BEH
DEM
ALC
DRU
SUI
Children and adolescents
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Depression DEP
Moderate-Severe Depression
In typical depressive episodes, the person experiences depressed 
mood, loss of interest and enjoyment, and reduced energy leading to 
diminished activity for at least 2 weeks. Many people with depression 
also suffer from anxiety symptoms and medically unexplained somatic 
symptoms.
This module covers moderate-severe depression across the lifespan, 
including childhood, adolescence, and old age.
A person in the mhGAP-IG category of Moderate-Severe Depression 
has difficulties carrying out his or her usual work, school, domestic 
or social activities due to symptoms of depression. 
The management of symptoms not amounting to moderate-severe 
depression is covered within the module on Other Significant 
Emotional or Medically Unexplained Somatic Complaints. » OTH
Of note, people currently exposed to severe adversity often experience 
psychological difficulties consistent with symptoms of depression but 
they do not necessary have moderate-severe depression. When 
considering whether the person has moderate-severe depression,  
it is essential to assess whether the person not only has symptoms 
but also has difficulties in day-to-day functioning due to the 
symptoms.
wire possition
Depression
Assessment and Management Guide
DEP1
 Check for recent bereavement or other major loss in 
prior 2 months.
»  Psychoeducation. » DEP 2.1
»  Address current psychosocial stressors. » DEP 2.2
»  Reactivate social networks. » DEP 2.3
»  Consider antidepressants.  » DEP 3
»  If available, consider interpersonal therapy, behavioural activation 
or cognitive behavioural therapy. » INT
»  If available, consider adjunct treatments: structured physical activity 
programme » DEP 2.4, relaxation training or problem-solving 
treatment. » INT 
»  DO NOT manage the complaint with injections or other ineffective 
treatments (e.g. vitamins). 
»  Offer regular follow-up. » DEP 2.5
Follow the above advice but DO NOT consider antidepressants or 
psychotherapy as ﬁ rst line treatment.  Discuss and support 
culturally appropriate mourning / adjustment.
»  Exit this module, and assess for Other signiﬁ cant Emotional 
or Medically unexplained somatic Complaints » OTH
If YEs to all 3 
questions then: 
moderate-severe 
depression is likely
1.  Does the person have moderate-
severe depression?
In case of recent 
bereavement or other 
recent major loss
»  For at least 2 weeks, has the person had at least 2 of the 
following core depression symptoms:
 –  Depressed mood (most of the day, almost every day), (for 
children and adolescents: either irritability or depressed mood)
 –  Loss of interest or pleasure in activities that are normally pleasurable
 –  Decreased energy or easily fatigued
»  During the last 2 weeks has the person had at least 3 other 
features of depression:
 –  Reduced concentration and attention
 –  Reduced self-esteem and self-confi dence
 –  Ideas of guilt and unworthiness
 –  Bleak and pessimistic view of the future
 –  Ideas or acts of self-harm or suicide
 –  Disturbed sleep 
 –  Diminished appetite 
»  Does the person have difﬁ culties carrying out usual work, 
school, domestic, or social activities? 
If NO to some or all 
of the three questions 
and if no other priority 
conditions have been 
identifi ed on the 
mhGAP-IG Master 
Chart 
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Depression DEP1
»  Ask about prior episode of manic symptoms such as extremely 
elevated, expansive or irritable mood, increased activity and 
extreme talkativeness, fl ight of ideas, extreme decreased need for 
sleep, grandiosity, extreme distractibility or reckless behaviour. 
See Bipolar Disorder Module. » BPD
»  (Re)consider risk of suicide / self-harm (see mhGAP-IG Master Chart)
»  (Re)consider possible presence of alcohol use disorder or 
other substance use disorder (see mhGAP-IG Master Chart)
»  look for concurrent medical illness, especially signs / symptoms 
suggesting hypothyroidism, anaemia, tumours, stroke, hypertension, 
diabetes, HIV / AIDS, obesity or medication use, that can cause or 
exacerbate depression (such as steroids)
3.  Does the person have depression 
with psychotic features (delusions, 
hallucinations, stupor)?
2.  Does the person have bipolar 
depression?
4.  Concurrent conditions
»  Augment above treatment for moderate-severe depression 
with an antipsychotic in consultation with a specialist.  
See Psychosis Module. » PsY
»  Manage both the moderate-severe depression and the 
concurrent condition.
»  Monitor adherence to treatment for concurrent medical illness, 
because depression may reduce adherence.
»  Manage the bipolar depression. 
See Bipolar Disorder Module. » BPD
Bipolar depression is likely if the 
person had:
»  3 or more manic symptoms lasting for 
at least 1 week OR 
»  A previously established diagnosis of 
bipolar disorder
If a concurrent 
condition is present
If YEs
Assessment and Management Guide
NOTE: People with bipolar depression are at risk 
of developing mania. Their treatment is different!
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Ask about: 
» Current known or possible pregnancy
» Last menstrual period, if pregnant
»  Whether person is breastfeeding
»  DO NOT prescribe antidepressant medication. 
»  Provide psychoeducation to parents. » DEP 2.1
»  Address current psychosocial stressors. » DEP 2.2
»  Offer regular follow-up. » DEP 2.5
»  DO NOT consider antidepressant as first-line treatment. 
»  Psychoeducation. » DEP 2.1
»  Address current psychosocial stressors. » DEP 2.2
»  If available, consider interpersonal psychotherapy (IPT) or cognitive 
behavioural therapy (CBT), behavioural activation. » INT
»  If available, consider adjunct treatments: structured physical  
activity programme » DEP 2.4, relaxation training or problem-
solving treatment. » INT
»  When psychosocial interventions prove ineffective, consider  
fluoxetine (but not other SSRIs or TCAs). » DEP 3
»  Offer regular follow-up. » DEP 2.5
Follow above treatment advice for the management of 
moderate-severe depression, but
»  During pregnancy or breast-feeding antidepressants should be 
avoided as far as possible.  
»  If no response to psychosocial treatment, consider using lowest 
effective dose of antidepressants.
» CONsulT A sPECIAlIsT  
»  If breast feeding, avoid long acting medication such as fluoxetine
If pregnant or  
breastfeeding
If 12 years or older
If younger than  
12 years
5.  Person is female of child- 
bearing age
6.  Person is a child or an adolescent
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Depression DEP2
2.1  Psychoeducation 
  (for the person and his or her family, as appropriate)
»  Depression is a very common problem that can happen  
to anybody.
»  Depressed people tend to have unrealistic negative opinions 
about themselves, their life and their future.
»  Effective treatment is possible. It tends to take at least a few 
weeks before treatment reduces the depression. Adherence 
to any prescribed treatment is important.
»  The following need to be emphasized:
 –  the importance of continuing, as far as possible, activities 
that used to be interesting or give pleasure, regardless 
of whether these currently seem interesting or give pleasure; 
 –  the importance of trying to maintain a regular sleep 
cycle (i.e., going to be bed at the same time every night, 
trying to sleep the same amount as before, avoiding 
sleeping too much); 
 –  the benefit of regular physical activity, as far as possible;
 –  the benefit of regular social activity, including 
participation in communal social activities, as far as 
possible;
 –  recognizing thoughts of self-harm or suicide and coming 
back for help when these occur;
 –  in older people, the importance of continuing to seek help 
for physical health problems.
2.2  Addressing current psychosocial stressors 
»  Offer the person an opportunity to talk, preferably in a 
private space. Ask for the person’s subjective understanding 
of the causes of his or her symptoms.
»  Ask about current psychosocial stressors and, to the extent 
possible, address pertinent social issues and problem-solve for 
psychosocial stressors or relationship difficulties with the help 
of community services / resources.
»  Assess and manage any situation of maltreatment, abuse 
(e.g. domestic violence) and neglect (e.g. of children or older 
people). Contact legal and community resources, as appropriate. 
»  Identify supportive family members and involve them  
as much as possible and appropriate.
»  In children and adolescents:  
 –  Assess and manage mental, neurological and  
substance use problems (particularly depression) in 
parents (see mhGAP-IG Master Chart). 
 –  Assess parents’ psychosocial stressors and manage  
them to the extent possible with the help of community 
services / resources.
 –  Assess and manage maltreatment, exclusion or bullying 
(ask child or adolescent directly about it). 
 –  If there are school performance problems, discuss with 
teacher on how to support the student.
 –  Provide culture-relevant parent skills training if available. » INT
2.3  Reactivate social networks 
»  Identify the person’s prior social activities that, if re-
initiated, would have the potential for providing direct or 
indirect psychosocial support (e.g. family gatherings, outings 
with friends, visiting neighbours, social activities at work 
sites, sports, community activities). 
»  Build on the person’s strengths and abilities and actively 
encourage to resume prior social activities as far as is 
possible. 
2.4  Structured physical activity programme  
(adjunct treatment option for moderate-severe depression) 
»  Organization of physical activity of moderate duration (e.g. 45 
minutes) 3 times per week. 
»  Explore with the person what kind of physical activity is more 
appealing, and support him or her to gradually increase the 
amount of physical activity, starting for example with 5 minutes 
of physical activity. 
2.5  Offer regular follow-up 
»  Follow up regularly (e.g. in person at the clinic, by phone, or 
through community health worker). 
» Re-assess the person for improvement (e.g. after 4 weeks).
 Psychosocial / Non-Pharmacological Treatment and Advice 
Intervention Details
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3.1  Initiating antidepressant medication
»  select an antidepressant
 –  Select an antidepressant from the National or WHO 
Formulary. Fluoxetine (but not other selective serotonin 
reuptake inhibitors (SSRIs)) and amitriptyline (as well as 
other tricyclic antidepressants (TCAs)) are antidepressants 
mentioned in the WHO Formulary and are on the WHO 
Model List of Essential Medicines. See » DEP 3.5
 –  In selecting an antidepressant for the person, consider the 
symptom pattern of the person, the side-effect profile of 
the medication, and the efficacy of previous antidepressant 
treatments, if any.
 –  For co-morbid medical conditions: Before prescribing anti- 
depressants, consider potential for drug-disease or drug-drug 
interaction. Consult the National or the WHO Formulary.
 –  Combining antidepressants with other psychotropic 
medication requires supervision by, or consultation with,  
a specialist.  
»  Tell person and family about:
 –  the delay in onset of effect; 
 –  potential side-effects and the risk of these symptoms, to 
seek help promptly if these are distressing, and how to 
identify signs of mania;
 –  the possibility of discontinuation / withdrawal symptoms on 
missing doses, and that these symptoms are usually mild 
and self-limiting but can occasionally be severe, particularly 
if the medication is stopped abruptly. However, antidepressants 
are not addictive;
 –  the duration of the treatment, noting that antidepressants 
are effective both for treating depression and for preventing 
its recurrence.
3.2  Precautions to be observed for 
antidepressant medication in special 
populations 
»  People with ideas, plans or acts of self-harm or suicide
 –  SSRIs are first choice. 
 –  Monitor frequently (e.g. once a week).
 –  To avoid overdoses in people at imminent risk of self-
harm / suicide, ensure that such people have access to a 
limited supply of antidepressants only (e.g. dispense for one 
week at a time). See Self-harm / Suicide Module.  » suI 1
»  Adolescents 12 years and older 
 –  When psychosocial interventions prove ineffective, consider 
fluoxetine (but not other SSRIs or TCAs).
 –  Where possible, consult mental health specialist when 
treating adolescents with fluoxetine.  
 –  Monitor adolescents on fluoxetine frequently (ideally once a 
week) for emergence of suicidal ideas during the first month 
of treatment. Tell adolescent and parent about increased risk 
of suicidal ideas and that they should make urgent contact if 
they notice such features.
»  Older people 
 –  TCAs should be avoided, if possible. SSRIs are first choice. 
 – Monitor side-effects carefully, particularly of TCAs. 
 –  Consider the increased risk of drug interactions, and give 
greater time for response (a minimum of 6 – 12 weeks before 
considering that medication is ineffective, and 12 weeks if 
there is a partial response within this period).
»  People with cardiovascular disease 
 –  SSRIs are first choice. 
 –  DO NOT prescribe TCAs to people at risk of serious cardiac 
arrhythmias or with recent myocardial infarction.  
 –  In all cardio-vascular cases, measure blood pressure before 
prescribing TCAs and observe for orthostatic hypotension 
once TCAs are started. 
3.3  Monitoring people on antidepressant 
medication 
»  If symptoms of mania emerge during treatment: immediately 
stop antidepressants and assess for and manage the mania and 
bipolar disorder.  » BPD
»  If people on SSRIs show marked / prolonged akathisia  
(inner restlessness or inability to sit still), review use of the medi- 
cation. Either change to TCAs or consider concomitant use of 
diazepam (5 – 10 mg / day) for a brief period (1 week). In case of 
switching to TCAs, be aware of occasional poorer tolerability 
compared to SSRIs and the increased risk of cardio-toxicity and 
toxicity in overdose.
»  If poor adherence, identify and try to address reasons for 
poor adherence (e.g. side-effects, costs, person’s beliefs 
about the disorder and treatment).
»  If inadequate response (symptoms worsen or do not improve 
after 4 – 6 weeks): review diagnosis (including co-morbid diagnoses) 
and check whether medication has been taken regularly and 
prescribed at maximum dose. Consider increasing the dose. If 
symptoms persist 4 – 6 weeks at prescribed maximum dose, 
then consider switching to another treatment (i.e., psychological 
treatment » INT, different class of antidepressants » DEP 3.5). 
Switch from one antidepressant to another with care, that is: stop 
the first drug; leave a gap of a few days if clinically possible; start 
the second drug. If switching is from fluoxetine to TCA the gap 
should be longer, for example one week.
 Antidepressant Medication
Depression DEP3
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»  If no response to adequate trial of two antidepressant 
medications or if no response on one adequate trial of 
antidepressants and one course of CBT or IPT: CONsulT A 
sPECIAlIsT  
3.4  Terminating antidepressant medication
»  Consider stopping antidepressant medication when the 
person (a) has no or minimal depressive symptoms for 9 – 12 
months and (b) has been able to carry out routine activities 
for that time period.
»  Terminate contact as follows:
 – In advance, discuss with person the ending of the treatment.
 –  For TCAs and most SSRIs (but faster for fluoxetine): Reduce 
doses gradually over at least a 4-week period; some people 
may require longer period.
 –  Remind the person about the possibility of discontinuation /
withdrawal symptoms on stopping or reducing the dose, 
and that these symptoms are usually mild and self-limiting 
but can occasionally be severe, particularly if the medication 
is stopped abruptly. 
  –  Advise about early symptoms of relapse (e.g. alteration in 
sleep or appetite for more than 3 days) and when to come 
for routine follow-up.
 – Repeat psychoeducation messages, as relevant. » DEP 2.1
»  Monitor and manage antidepressant withdrawal 
symptoms (common: dizziness, tingling, anxiety, irritability, 
fatigue, headache, nausea, sleep problems)
 –  Mild withdrawal symptoms: reassure the person and  
monitor symptoms.
 –  Severe withdrawal symptoms: reintroduce the 
antidepressant at the effective dose and reduce more 
gradually. 
 –  CONsulT A sPECIAlIsT  if significant 
discontinuation / withdrawal symptoms persist.
»  Monitor re-emerging depression symptoms during 
withdrawal of antidepressant: prescribe the same 
antidepressant at the previous effective dose for another 12 
months if symptoms re-emerge.
Depression DEP3
Intervention Details
15
Depression DEP3
Intervention Details
3.5 Information on SSRIs and TCAs
selective serotonin Reuptake Inhibitors (ssRIs; e.g. fluoxetine) 
serious side-effects (these are rare)
»  marked / prolonged akathisia (inner restlessness or inability to sit still);
»  bleeding abnormalities in those who regularly use aspirin and other non-steroidal anti-inflammatory drugs.
Common side-effects  
(most side-effects diminish after a few days; none are permanent)
»  restlessness, nervousness, insomnia, anorexia and other gastrointestinal disturbances, headache, sexual 
dysfunction. 
Cautions
»  risk of inducing mania in people with bipolar disorder.
Time to response after initiation of adequate dose
»  4 – 6 weeks.
Dosing fluoxetine in healthy adults
»  Initiate treatment with 20 mg daily (to reduce risk of side effects that undermine adherence, one may start at 
10 mg (e.g. half a tablet) once daily and increase to 20 mg if the medication is tolerated).
»  If no response in 4 – 6 weeks or partial response in 6 weeks, increase dose by 20 mg (maximum dose 60 mg) 
according to tolerability and symptom response.
Dosing fluoxetine in adolescents
»  Initiate treatment with 10 mg (e.g. half a tablet) once daily and increase to 20 mg after 1 – 2 weeks  
(maximum dose 20 mg)
»  If no response in 6 – 12 weeks or partial response in 12 weeks, consult a specialist.
Dosing fluoxetine in elderly or medically ill
»  Initiate treatment with 10 mg tablet (if available) once daily or 20 mg every other day for 1 – 2 weeks and then 
increase to 20 mg if tolerated.
»  If no response in 6 – 12 weeks or partial response in 12 weeks, increase dose gradually (maximum dose 60 mg). 
Increase dose more gradually than in healthy adults.
Tricyclic antidepressants (TCAs; e.g. amitriptyline) 
serious side-effects (these are rare)
»  cardiac arrhythmia. 
Common side-effects  
(most side-effects diminish after a few days; none are permanent)
»  orthostatic hypotension (fall risk), dry mouth, constipation, difficulty urinating, dizziness, blurred vision and 
sedation.
Cautions
»  risk of switch to mania, especially in people with bipolar disorder;
»  impaired ability to perform certain skilled tasks (e.g. driving) – take precautions until accustomed to medication;
»  risk of self-harm (lethal in overdose); 
»  less effective and more severe sedation if given to regular alcohol users.
Time to response after initiation of adequate dose
»  4 – 6 weeks (pain and sleep symptoms tend to improve in a few days).
Dosing amitriptyline in healthy adults
»  Initiate treatment with 50 mg at bedtime.
»  Increase by 25 to 50 mg every 1 – 2 weeks, aiming for 100 – 150 mg by 4 – 6 weeks depending on response and 
tolerability. 
»  If no response in 4 – 6 weeks or partial response in 6 weeks, increase dose gradually (maximum dose 200 mg) in divided 
doses (or a single dose at night).
Dosing amitriptyline in adolescents
»  DO NOT prescribe amitriptyline in adolescents. 
Dosing amitriptyline in elderly or medically ill 
»  Initiate with 25 mg at bedtime.
»  Increase by 25 mg weekly, aiming for a target dose of 50 – 75 mg by 4 – 6 weeks.
»  If no response in 6 – 12 weeks or partial response in 12 weeks, increase dose gradually (maximum dose 100 mg) in 
divided doses. 
»  Monitor for orthostatic hypotension.
This information is for quick reference only and is not intended to be an exhaustive guide to the medications, their dosing and side-effects.  
Additional details are given in “Pharmacological Treatment of Mental Disorders in Primary Health Care” (WHO, 2009)  
(http://www.who.int/mental_health/management/psychotropic/en/index.html).
16Depression » Intervention Details
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Psychosis PSY
Psychosis is characterized by distortions of thinking and  
perception, as well as inappropriate or narrowed range of  
emotions. Incoherent or irrelevant speech may be present.  
Hallucinations (hearing voices or seeing things that are not there), 
delusions (fixed, false idiosyncratic beliefs) or excessive and  
unwarranted suspicions may also occur. Severe abnormalities of 
behaviour, such as disorganized behaviour, agitation, excitement 
and inactivity or overactivity, may be seen. Disturbance of  
emotions, such as marked apathy or disconnect between reported 
emotion and observed affect (such as facial expressions and  
body language), may also be detected. People with psychosis  
are at high risk of exposure to human rights violations.
wire possition
Psychosis PSY1
»  Provide education to the person and carers about 
psychosis and its treatment. » pSY 2.1
»  Begin antipsychotic medication.  » pSY 3.1
»  If available, provide psychological and social interventions, 
such as family therapy or social skills therapy. » InT
»  Facilitate rehabilitation. » pSY 2.2
»  Provide regular follow-up. » pSY 2.3
»  Maintain realistic hope and optimism. 
  noTe: Do noT prescribe anticholinergic medication 
routinely to prevent antipsychotic side-effects. 
»  Provide education to the person and carers. » pSY 2.1
  IF THe peRSon IS noT on AnY TReATMenT, 
START TReATMenT AS FoR ACuTe pSYCHoTIC 
epISoDe.
»  Review and ensure treatment adherence.
»  If the person is not responding adequately, consider increasing 
current medication or changing it.  » pSY 3.1 and 3.2
»  If available, provide psychological and social interventions 
such as family therapy or social skills therapy. Consider 
adding a psychosocial intervention not offered earlier, e.g. 
cognitive behavioural therapy if available. » InT
»  Provide regular follow-up. » pSY 2.3
»  Maintain realistic hope and optimism. 
»  Facilitate rehabilitation. » pSY 2.2 
If symptoms persist for more 
than 3 months 
chronic psychosis is likely
1.  Does the person have 
acute psychosis?
2.  Does the person have 
chronic psychosis?
»  Incoherent or irrelevant speech
»  Delusions
»  Hallucinations
»  Withdrawal, agitation, disorganized behaviour 
»  Beliefs that thoughts are being inserted or broadcast from 
one’s mind
»  Social withdrawal and neglect of usual responsibilities related to 
work, school, domestic or social activities
Ask the person or carer 
»  When this episode began 
»  Whether any prior episodes occurred
»  Details of any previous or current treatment
If multiple symptoms are 
present, psychosis is likely.
If this episode is: 
»  the ﬁ rst episode OR 
»  a relapse OR
»  worsening of psychotic 
symptoms
it is an acute psychotic 
episode 
Rule out psychotic symptoms due to:
»  Alcohol or drug intoxication or withdrawal
(Refer to Alcohol use disorder / Drug use disorder 
module  » AlC and  » DRu )
»  Delirium due to acute medical conditions 
such as cerebral malaria, systemic infections / 
sepsis, head injury
Assessment and Management Guide
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Psychosis PSY1
look for: 
»  Several days of: 
 –  Markedly elevated or irritable mood 
 –  Excessive energy and activity
 –  Excessive talking
 –  Recklessness
»  Past history of:
 – Depressed mood 
 –  Decreased energy and activity 
(see Depression Module for details). » Dep
3.  Is the person having an 
acute manic episode?
»  Exit this module and go to 
Bipolar Disorder Module. » BpD
If yes, this could be 
bipolar disorder
Assessment and Management Guide
» Alcohol use or drug use disorders
»  Suicide / self-harm
»  Dementia
»  Concurrent medical illness: Consider especially signs/symptoms 
suggesting stroke, diabetes, hypertension, HIV/AIDS, cerebral 
malaria or medications (e.g. steroids)
4.  Look for concurrent conditions
Woman of child-bearing age?
»  Manage both the psychosis and the concurrent condition. 
»  In the case of a pregnant woman, liaise with the maternal health 
specialist, if available, to organize care.  
»  Explain the risk of adverse consequences for the mother and her 
baby, including the risk of obstetric complications and psychotic 
relapse (particularly if medication is changed or stopped).
»  Women with psychosis who are planning a pregnancy, pregnant, or 
breastfeeding should be treated with low-dose oral haloperidol or 
chlorpromazine.
» Avoid routine use of depot antipsychotics.
If yes, then 
noTe: 
»  People who suffer only manic episodes 
(without depression) are also classiﬁ ed 
as having bipolar disorder.
»  Complete recovery between episodes is 
common in bipolar disorder.
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Psychosis PSY2
2.1  Psychoeducation
» Messages to the person with psychosis 
 – the person’s ability to recover; 
 –  the importance of continuing regular social, educational 
and occupational activities, as far as possible;
 – the suffering and problems can be reduced with treatment;
 – the importance of taking medication regularly;
 –  the right of the person to be involved in every decision that 
concerns his or her treatment;
 –  the importance of staying healthy (e.g. healthy diet, staying 
physically active, maintaining personal hygiene).
»  Additional messages to family members of people 
with psychosis
 –  The person with psychosis may hear voices or may ﬁ rmly 
believe things that are untrue. 
 –  The person with psychosis often does not agree that he or 
she is ill and may sometimes be hostile. 
 –  The importance of recognizing the return/worsening of 
symptoms and of coming back for re-assessment should 
be stressed.
 –  The importance of including the person in family and other 
social activities should be stressed. 
 –  Family members should avoid expressing constant or severe 
criticism or hostility towards the person with psychosis.
 –  People with psychosis are often discriminated against but 
should enjoy the same rights as all people. 
 –  A person with psychosis may have difﬁ culties recovering or 
functioning in high-stress working or living environments. 
 –  It is best for the person to have a job or to be otherwise 
meaningfully occupied.
»  If needed and available, explore housing/assisted living 
support. Consider carefully the person’s functional capacity 
and the need for support in advising and facilitating optimal 
housing arrangements, bearing in mind the human rights of 
the person.
2.3  Follow-up 
»  People with psychosis require regular follow-up. 
»  Initial follow-up should be as frequent as possible, even daily, 
until acute symptoms begin to respond to treatment. Once 
the symptoms have responded, monthly to quarterly follow-up 
is recommended based on clinical need and feasibility factors 
such as staff availability, distance from clinic, etc. 
»  Maintain realistic hope and optimism during treatment.
»  At each follow-up, assess symptoms, side-effects of 
medications and adherence. Treatment non-adherence is 
common and involvement of carers is critical during such 
periods.
»  Assess for and manage concurrent medical conditions.
»  Assess for the need of psychosocial interventions at each 
follow-up.
 –  In general, it is better for the person to live with family or 
community members in a supportive environment outside 
hospital settings. Long-term hospitalization should be 
avoided.
2.2  Facilitate rehabilitation in the community 
»  Coordinate interventions with health staff and with 
colleagues working in social services, including organizations 
working on disabilities.
»  Facilitate liaison with available health and social resources to 
meet the family’s physical, social and mental health needs. 
»  Actively encourage the person to resume social, educational 
and occupational activities as appropriate and advise family 
members about this. Facilitate inclusion in economic and 
social activities, including socially and culturally appropriate 
supported employment. People with psychosis are often 
discriminated against, so it is important to overcome internal 
and external prejudices and work toward the best quality of 
life possible. Work with local agencies to explore employment 
or educational opportunities, based on the person’s needs 
and skill level. 
 Psychosocial Interventions
Involve people with psychosis and their carers actively 
in the design, implementation and evaluation of these 
interventions.
Intervention Details
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Psychosis PSY3
3.1 Initiating antipsychotic medications 
»  For prompt control of acute psychotic symptoms, health-care 
providers should begin antipsychotic medication immediately 
after assessment. Consider acute intramuscular treatment 
only if oral treatment is not feasible. Do not prescribe depot / 
long-term injections for prompt control of acute psychotic 
symptoms.
» Prescribe one antipsychotic medication at a time.
»  “Start low, go slow”: Start with a low dose within the 
therapeutic range (see the antipsychotic medication table for 
details) and increase slowly to the lowest effective dose, in 
order to reduce the risk of side-effects.
»  Try the medication at an optimum dose for at least 4 – 6 
weeks before considering it ineffective.
»  Oral haloperidol or chlorpromazine should be routinely 
offered to a person with psychotic disorder.
 Pharmacological Interventions
Table: Antipsychotic Medications
Medication: Haloperidol Chlorpromazine Fluphenazine  
depot / long-acting
Starting dose: 1.5 – 3 mg 75 mg 12.5 mg
Typical effective dose (mg): 3 – 20 mg / day 75 – 300 mg / day* 12.5 – 100 mg every 2 – 5 weeks
Route: oral / intramuscular (for acute 
psychosis)
oral deep intramuscular injection 
in gluteal region
Significant side-effects:
Sedation: + +++ +
Urinary hesitancy: + ++ +
Orthostatic hypotension: + +++ +
Extrapyramidal side-effects: ** +++ + +++
Neuroleptic malignant  
syndrome: ***
rare rare rare
Tardive dyskinesia: **** + + +
ECG changes: + + +
Contraindications: impaired consciousness,  
bone marrow depression, 
pheochromocytoma, porphyria, 
basal ganglia disease
impaired consciousness, bone 
marrow depression, 
pheochromocytoma
children, impaired 
consciousness, parkinsonism, 
marked cerebral 
atherosclerosis
   This table is for quick reference only and is not intended to be an exhaustive guide to the medications, their dosing and side-effects.  
Additional details are given in “Pharmacological Treatment of Mental Disorders in Primary Health Care” (WHO, 2009)  
(http://www.who.int/mental_health/management/psychotropic/en/index.html).
 *  Up to 1 g maybe necessary in severe cases.
 **  Extrapyramidal symptoms include acute dystonic reactions, tics, tremor, and cogwheel and muscular rigidity.
 ***  Neuroleptic malignant syndrome is a rare but potentially life-threatening disorder characterized by muscular rigidity, elevated temperature and high blood pressure. 
 ****  Tardive dyskinesia is a long-term side-effect of antipsychotic medications characterized by involuntary muscular movements, particularly of the face, hands and trunk.
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 Pharmacological Interventions
3.2  Monitoring people on antipsychotic 
medication
»  If the response is inadequate to more than one 
antipsychotic medication using one medicine at a time 
at adequate dosage for adequate duration: 
 –  Review diagnosis (and any co-morbid diagnoses).
 –  Rule out psychosis induced by alcohol or psychoactive  
substance use (even if it was ruled out initially).
 –  Ensure treatment adherence; consider depot / long-acting 
injectable antipsychotic with a view to improve adherence.
 –  Consider increasing current medication or switching to 
another medication. 
 –  Consider second-generation antipsychotics (with the 
exception of clozapine), if cost and availability is not a 
constraint, as an alternative to haloperidol or 
chlorpromazine. 
 –  Consider clozapine for those who have not responded to 
other antipsychotic agents at adequate dosages for adequate 
duration. Clozapine may be considered by non-specialist 
health-care providers, preferably under the supervision of 
mental health professionals. It should only be considered if 
routine laboratory monitoring is available, because of the risk 
of life-threatening agranulocytosis.
»  If extrapyramidal side-effects (such as parkinsonism or 
dystonia) occur: 
 –  Reduce the dose of antipsychotic medication, and 
 –  Consider switching to another antipsychotic (e.g. switching 
from haloperidol to chlorpromazine).
 –  Consider anticholinergic medications for short-term use if 
these strategies fail or extrapyramidal side-effects are acute, 
severe or disabling.
  Anticholinergic medications
  Biperiden, if needed, should be started at 1 mg twice daily, 
increasing to a target dose of 3 – 12 mg per day, oral or 
intravenous. Side-effects include sedation, confusion and 
memory disturbance, especially in the elderly. Rare side-effects 
include angle-closure glaucoma, myasthenia gravis, 
gastrointestinal obstruction.
  Trihexyphenidyl (Benzhexol) can be used as an alternate 
medicine at 4 – 12 mg per day. Side-effects are similar to those 
of biperiden.
3.3  Discontinuation of antipsychotic  
medications
»  For acute psychosis, continue antipsychotic treatment  
for 12 months after full remission. 
»  For people with chronic psychosis, consider treatment 
discontinuation if the person has been stable for several 
years, weighing the increased risk of relapse following 
discontinuation against possible medication side-effects, 
while taking into account patient preferences in consultation 
with the family.
»  If possible, ConSulT A SpeCIAlIST  regarding the 
decision to discontinue antipsychotic medication.
22Psychosis » Intervention Details
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Bipolar Disorder BPD
Bipolar disorder is characterized by episodes in which the  
person’s mood and activity levels are significantly disturbed. 
This disturbance consists on some occasions of an elevation  
of mood and increased energy and activity (mania), and  
on others of a lowering of mood and decreased energy and 
activity (depression). Characteristically, recovery is complete  
between episodes. People who experience only manic episodes 
are also classified as having bipolar disorder.
wire possition
Assessment and Management Guide
Bipolar Disorder BPD 1
»  Begin treatment of acute mania with lithium, valproate, 
carbamazepine or with antipsychotics.  » BPD 3.1
»  Consider a short-term benzodiazepine  
(such as diazepam) for behavioural disturbance 
or agitation. » BPD 3.2
»  Discontinue any antidepressants. » BPD 3.3
»  Advise the person to modify lifestyle; provide 
information about bipolar disorder and its treatment. 
» BPD 2.1
»  Provide regular follow-up. » BPD 2.4
1.  Is the person in a manic state?
look for:
»  Elevated, expansive or irritable mood 
»  Increased activity, restlessness, excitement
»  Increased talkativeness
»  Loss of normal social inhibitions
»  Decreased need for sleep
»  Inﬂ ated self-esteem
»  Distractibility
»  Elevated sexual energy or sexual indiscretion
Ask about: 
»  Symptom duration
»  Whether symptoms interfered with usual responsibilities related to 
work, school, domestic or social activities
»  Whether hospitalization was required
if the person has: 
»  multiple symptoms 
»  lasting for at least 1 week
»  severe enough to interfere 
signifi cantly with work and 
social activities or requiring 
hospitalization
mania is likely
2.  Does the person have a known 
prior episode of mania but now has 
depression?
 (Assess according to Depression Module » DEP )
»  Begin treatment with a mood-stabilizer.  » BPD 4
»  Consider antidepressant combined with mood stabilizer for 
moderate / severe depression according to suggestions in 
Depression Module.  » DEP
  inform the person about the risk of switching to mania 
before starting antidepressant medication
»  Advise the person to modify lifestyle; provide information about 
bipolar disorder and its treatment. » BPD 2.1
»  Reactivate social networks. » BPD 2.2 
»  If available, consider psychological interventions. » int 
»  Pursue rehabilitation, including appropriate economic and educa-
tional activities, using formal and informal systems. » BPD 2.3
»  Provide regular follow-up. » BPD 2.4
if YES, then 
bipolar depression 
is likely.
if manic symptoms are associated with drug intoxication, 
refer to Drug use Disorders Module  » DRu
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Bipolar Disorder BPD 1
»  Alcohol use or drug use disorders
»  Dementia 
»  Suicide / self-harm
»  Concurrent medical illness, especially hyper- or hypothyroidism, 
renal or cardiovascular disease
3.  Look for presence of concurrent 
conditions
»  Manage both the bipolar disorder and the concurrent condition. if YES
4.  Is the person not currently manic or 
depressed but has a history of mania?
»  If the person is not on a mood stabilizer then begin one.
 » BPD 4
»  Advise person to modify lifestyle; provide information 
about bipolar disorder and its treatment. » BPD 2.1
»  Reactivate social networks. » BPD 2.2
»  Pursue rehabilitation, including appropriate economic 
and educational activities, using formal and informal 
systems. » BPD 2.3
»  Provide regular follow-up; monitor side-effects and 
adherence. » BPD 2.4
This person most likely has 
bipolar disorder and is currently 
between episodes.
Relapse prevention is needed 
if the person has had:
»  2 or more acute episodes 
(e.g. 2 episodes of mania, or 
one episode of mania and 
one episode of depression) 
oR 
»  a single manic episode 
involving signifi cant risk and 
adverse consequences
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5.  Is the person in a special group?
» Use lower doses of medication.
» Anticipate increased risk of drug interactions.
» Presenting symptoms may be atypical.
» Take special care to ensure adherence to treatment.
» conSult A SPEciAliSt, if available. 
» conSult A SPEciAliSt, if available.  
» Avoid starting treatment with a mood stabilizer. 
» Consider low-dose haloperidol (with caution). 
»  If a pregnant woman develops acute mania while taking a mood 
stabilizer, consider changing to low-dose haloperidol.
»  Elderly
»  Adolescent
»  Pregnant or 
breast-feeding
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Bipolar Disorder BPD 2
2.1  Psychoeducation  
Messages to people with bipolar disorder (not currently  
in acute manic state) and to family members of people with 
bipolar disorder
»  Explanation: Bipolar disorder is a mental health condition 
that tends to involve extreme moods, which may go from 
feeling very depressed and fatigued to feeling extremely  
energetic, irritated and overly excited.
»  There needs to be some method for monitoring mood, 
such as keeping a daily mood log in which irritability, anger  
or euphoria are recorded. 
»  It is important to maintain a regular sleep cycle (e.g. going 
to bed at the same time every night, trying to sleep the same 
amount as before illness, avoiding sleeping much less than usual).
»  Relapses need to be prevented, by recognizing when 
symptoms return, such as sleeping less, spending more money 
or feeling much more energetic than usual, and coming back 
for treatment when these occur. 
»  A person in a manic state lacks insight into the illness and 
may even enjoy the euphoria and improved energy, so carers 
must be part of relapse prevention. 
»  Alcohol and other psychoactive substances should be 
avoided. 
»  Since lifestyle changes should be continued as long as 
needed, potentially indefinitely, they should be planned and 
developed for sustainability.
»  The person should be encouraged to seek support after 
significant life events (e.g. bereavement) and to talk to family 
and friends.
»  General coping strategies, such as planning a regular work 
or school schedule that avoids sleep deprivation, improving 
social support systems, discussing and soliciting advice about 
major decisions (especially ones involving money or major 
commitments) need to be enhanced. 
»  The family’s physical, social and mental health needs 
should be considered. 
»  Build rapport: Mutual trust between the person and the 
health-care staff is critical for a person with bipolar disorder, 
since a positive therapeutic alliance may improve the long-
term outcome, especially by improving treatment adherence.
2.2  Reactivate social networks
»  Identify the person’s prior social activities that, if reinitiated, 
would have the potential for providing direct or indirect 
psychosocial support (e.g. family gatherings, outings with 
friends, visiting neighbours, social activities at work sites, 
sports, community activities).
»  Actively encourage the person to resume these social 
activities and advise family members about this.
2.3  Rehabilitation
»  Facilitate opportunities for people and their carers to be included in 
economic, educational and cultural activities appropriate to their 
cultural environment, using available formal and informal systems. 
»  Consider supported employment for those who have difficulty 
obtaining or retaining normal employment.
2.4  Follow-up 
»  Regular follow-up is required. The relapse rate is high and 
those in a manic state are often unable to see the need for 
treatment, so treatment non-adherence is common and 
involvement of carers is critical during such periods.
»  At each follow-up, assess symptoms, side-effects of medica-
tions, adherence and the need for psychosocial interventions.
»  A person with mania should return for evaluation as frequently 
as warranted. The evaluation should be more frequent until 
the manic episode is over.
»  Provide information about the illness and treatment to the person 
and their carers, particularly regarding the signs and symptoms of 
mania, the importance of regular adherence to medication, even in 
the absence of symptoms, and the characteristic difficulty the person 
may sometimes have in understanding the need for treatment. If a 
person has no carer or person at least to check on them periodi-
cally, encourage recruiting someone from the person’s commu-
nity, ideally someone from their network of friends and family.
 Psychosocial interventions
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Bipolar Disorder BPD 3
 Treatment of acute mania
3.1  Lithium, valproate, carbamazepine or 
antipsychotics
Consider lithium, valproate, carbamazepine or antipsychotics for 
treatment of acute mania. Lithium may be considered only if clinical 
and laboratory monitoring are available. If symptoms are severe, 
consider using an antipsychotic, since onset of effectiveness is more 
rapid than with mood stabilizers.
For details regarding dose, monitoring, adverse effects, etc, see 
the section on mood stabilizers in the maintenance treatment of 
bipolar disorders and the table on mood stabilizers. » BPD 4
For details of the use of antipsychotics, refer to the Psychosis 
Module, pharmacological interventions.  » PSY 2
3.2  Benzodiazepines
Person in a manic state who is experiencing agitation may  
benefit from short-term use of a benzodiazepine such as  
diazepam.
Benzodiazepines should be discontinued gradually as soon as 
symptoms improve, as tolerance can develop.
3.3  Antidepressants
If mania develops in a person on antidepressants, stop  
the antidepressants as soon as possible, abruptly or gradually, 
weighing the risk of discontinuation symptoms (refer to  
Depression Module, pharmacological interventions, see » DEP) 
against the risk of the antidepressant worsening the mania.  
People with bipolar disorder should not receive antidepressants 
alone because of the risk of inducing mania, particularly with 
tricyclic antidepressants. Antidepressants are less likely to induce 
mania when prescribed in conjunction with lithium, antipsychotic 
therapy or valproate.
3.4  Monitoring
Treatment should be regularly monitored and its effect assessed 
after 3 and 6 weeks.
If the person has not improved after 6 weeks, consider switching  
to a medication that has not been tried, or adding another 
medication in combination therapy, such as an antipsychotic 
plus a mood stabilizer. If combination therapy proves ineffective, 
conSult A SPEciAliSt.  
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Bipolar Disorder BPD 4
 Maintenance treatment of bipolar disorders
Choosing a mood stabilizer 
(lithium, valproate, carbamazepine)
4.1 Lithium
»  Consider lithium only if clinical and laboratory monitoring is 
available. 
»  Lithium monotherapy is effective against the relapse of both 
mania and depression, although it is most effective as an 
antimanic agent. 
»  Before beginning lithium therapy, obtain renal function tests, 
thyroid function tests, complete blood count, electrocardio-
gram and a pregnancy test, if possible.
»  Start with a low dose (300 mg at night) increasing gradually 
while monitoring the blood concentration every 7 days until it 
is 0.6 – 1.0 mEq / litre. Once therapeutic blood levels have been 
achieved, check the blood levels every 2 – 3 months. 
»  It takes at least 6 months to determine lithium’s full effective-
ness as maintenance treatment in bipolar disorder.
»  Advise the person to maintain ﬂ uid intake, particularly after 
sweating, or if immobile for long periods or febrile.
»  Seek medical attention if the person develops diarrhoea or 
vomiting.
»  A person taking lithium should avoid over-the-counter non-
steroidal anti-inﬂ ammatory drugs.
»  If a severe metabolic or respiratory disturbance occurs, con-
sider stopping lithium treatment for up to 7 days.
4.2 Valproate
»  Before beginning valproate treatment, take a history of cardio-
vascular, renal or hepatic disease.
»  Start with a low dose (500 mg / day), increasing (as tolerated) to 
the target dose. 
»  Monitor closely for response, side-effects and adherence. Ex-
plain the signs and symptoms of blood and liver disorders, and 
advise the person to seek immediate help if these develop. 
»  Reduce the dose of medication if intolerable side-effects persist. 
If reduction in dose does not help, consider switching to another 
antimanic agent.
4.3 Carbamazepine
»  If lithium and valproate are ineffective or poorly tolerated, or 
if therapy with one of these agents is not feasible, consider 
carbamazepine.
»  Before and during carbamazepine therapy, take a history of 
cardiovascular, renal or hepatic disease. 
»  Start with a low dose (200 mg / day at bedtime) and slowly 
increase until a dose of 600 – 1000 mg / day is achieved. 
»  Health-care providers should consider that the dose may need 
to be adjusted after 2 weeks due to hepatic enzyme induction.
 
»  Reduce the dose of medication if intolerable side-effects persist. 
If reduction in dose does not help, consider switching to 
another antimanic agent.
notE: Lithium treatment requires close monitoring of 
serum level, since the medication has a narrow therapeutic 
range. In addition, thyroid function must be checked 
every 6 – 12 months. If laboratory examinations are not 
available or feasible, lithium should be avoided. Erratic 
compliance or stopping lithium treatment suddenly may 
increase the risk of relapse. Do not prescribe lithium 
where the lithium supply may be frequently interrupted.
Avoid lithium, valproate and carbamazepine in pregnant 
women, and weigh the risks and benefi ts in women of 
childbearing age. 
If the person has frequent relapses or continuing 
functional impairment, consider switching to a different 
mood stabilizer or adding a second mood stabilizer. 
conSult A SPEciAliSt.  
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Medication: Lithium Valproate Carbamazepine
Starting dose (mg): 300 500 200
typical effective dose (mg): 600 – 1200 1000 – 2000 400 – 600
Route: oral oral oral
target blood level: 0.6 – 1.0 mEq / litre
mania: 0.8 – 1.0 mEq / litre;
maintenance: 0.6 – 0.8 mEq / litre.
Regular serum level monitoring
is critical.
Not routinely  
recommended
Not routinely  
recommended
noteworthy side effects: Impaired coordination, polyuria, 
polydypsia, cognitive problems, 
cardiac arrhythmias, diabetes 
insipidus, hypothyroidism 
Caution if there is underlying 
hepatic disease. Hair loss 
and, rarely, pancreatitis are 
possible.
Diplopia, impaired coordi-
nation, rash, liver enzyme 
elevations;
Rarely: Stevens-Johnson  
syndrome, aplastic anaemia.
Sedation: ++ ++ ++
Tremor: ++ ++ ++
Weight gain: ++ ++ ++
Hepatotoxicity: - ++ +
Thrombocytopenia: - + +
Leucopoenia, mild asymptomatic: - + +
4.4 Discontinuation of mood stabilizers
»  In a person not currently in a manic or depressed state  
(bipolar disorder between episodes), follow up every 3 
months. Continue treatment and monitor closely for relapse. 
»  Continue maintenance treatment with the mood stabilizer  
for at least 2 years after the last bipolar episode. 
»  However, if a person has had severe episodes with psychotic 
symptoms or frequent relapses, conSult A SPEciAliSt  
regarding the decision to discontinue maintenance treatment 
after 2 years.
»  When discontinuing medications, reduce gradually over a 
period of weeks or months.
»  If switching to another medication, begin that medication 
first and treat with both medications for 2 weeks before 
tapering off the first medication. 
Table: Mood Stabilizers
This table is for quick reference only and is not intended to be an exhaustive guide to the medications, their dosing and  
side-effects. Additional details are given in “Pharmacological Treatment of Mental Disorders in Primary Health Care” (WHO, 2009) 
(http://www.who.int/mental_health/management/psychotropic/en/index.html). 
Intervention Details
Bipolar Disorder BPD 4
 Maintenance treatment of bipolar disorders
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Epilepsy / Seizures EPI
Epilepsy is a chronic condition, characterized by recurrent  
unprovoked seizures. It has several causes; it may be genetic or  
may occur in people who have a past history of birth trauma, 
brain infections or head injury. In some cases, no specific cause 
can be identified. Seizures are caused by abnormal discharges  
in the brain and can be of different forms; people with epilepsy 
can have more than one type of seizure. The two major forms 
of seizures are convulsive and non-convulsive. Non-convulsive 
epilepsy has features such as change in awareness, behaviour, 
emotions or senses (such as taste, smell, vision or hearing) 
similar to mental health conditions, so may be confused with 
them. Convulsive epilepsy has features such as sudden muscle 
contraction, causing the person to fall and lie rigidly, followed 
by the muscles alternating between relaxation and rigidity,  
with or without loss of bowel or bladder control. This type is 
associated with greater stigma and higher morbidity and  
mortality. This module covers only convulsive epilepsy.
wire possition
Assessment and Management Guide » for Emergency Cases
Epilepsy / Seizures EPI 1
»  Check airway, breathing and circulation. 
»  Protect person from injury: make sure they are in a safe place away from 
fi re or other things that might injure them. 
»  DO NOT leave the person alone. Seek help if possible. 
»  Put the person on their side to prevent aspiration.
»  DO NOT put anything into the mouth. 
» Manage the convulsions as above.
 REFER PERSON URGENTLY TO HOSPITAL.
»  Head or neck injury: DO NOT move neck because of possible cervical spine 
injury.  Log-roll person when moving.
»  Neuroinfection: Manage the infection according to local guidelines.
1.  Is the person convulsing or 
unconscious?
Measure 
»  Blood pressure, temperature and respiratory rate
Look for:
»  Signs of serious head and spine trauma
»  Pupils: dilated or pinpoint? not equal? 
not reactive to light?
»  Signs of meningitis
»  Focal defi cits
Ask about:
»  If unconscious, ask accompanying person: “Has there 
been a recent convulsion?”
» Duration of impaired consciousness / convulsion
» Number of convulsions
» History of head trauma or neck injury
»  Other medical problems, medications or poisons 
(e.g. organophosphate poisoning), substance use (such as 
stimulant intoxication, benzodiazepine or 
alcohol withdrawal » ALC and » DRU)
»  A history of epilepsy
In all cases
If they are 
convulsing
Rule out 
pregnancy
 If in second half of 
pregnancy or up to 1 
week post partum
 
AND no past history 
of epilepsy,
suspect eclampsia
If head or neck 
injury, or neuroin-
fection suspected
ASSESSMENT AND MANAGEMENT IN 
EMERGENCY CASES SHOULD PROCEED 
SIMULTANEOUSLY!
»  Insert an intravenous (i.v.) line and give fl uids slowly (30 drops / minute).
»  Give glucose i.v. (5 ml of 50 % glucose in adults; 
2 – 5 ml / kg of 10 % glucose in children).
»  Give diazepam i.v. 10 mg slowly (child: 1 mg / year of age) or 
lorazepam i.v. 4 mg (0.1 mg / kg), if available.
»  Give diazepam rectally (same dose as above) if i.v. line is diffi cult to establish. 
»  DO NOT give intramuscular (i.m.) diazepam 
  If convulsion does not stop after 10 minutes of fi rst dose of diazepam, 
give second dose of diazepam or lorazepam (same dose as fi rst) and
 REFER PERSON URGENTLY TO HOSPITAL.
»  DO NOT give more than two doses of diazepam. 
»  Give magnesium sulfate 10 g i.m.: Give 5 g (10 ml of 50 % solution) i.m. deep in 
upper outer quadrant of each buttock with 1 ml of 2 % lignocaine in the same syringe.
»  If diastolic blood pressure is > 110 mmHg: Give hydralazine 5 mg i.v. slowly 
(3 – 4 minutes). If i.v. is not possible, give i.m. If diastolic blood pressure remains 
> 90 mmHg, repeat the dose at 30 minute intervals until diastolic blood pressure 
is around 90 mmHg. Do not give more than 20 mg in total.
  REFER PERSON URGENTLY TO HOSPITAL and follow local guidelines 
for management of pregnancy, childbirth and postpartum care.
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 REFER PERSON URGENTLY TO HOSPITAL and manage in hospital.
»  Check airway, breathing, circulation.
»  Administer oxygen. 
»  Check need for intubation / ventilation when multiple doses of various 
medications are being administered.
»  Put the person on their side to prevent aspiration 
»  DO NOT put anything into the mouth during a convulsion. 
Give :
»  Phenobarbital 10 – 15 mg / kg, i.v. (rate of 100 mg / minute).
OR 
»  Phenytoin 15 – 18 mg / kg i.v. (through different line to diazepam) over 
60 minutes. It is critical to have a very good i.v. line as the drug is very 
caustic and will cause signifi cant local damage if it extravasates. 
If seizures continue:
»  Give the other drug (if available) OR
 additional phenytoin 10 mg / kg i.v. (through different line to diazepam) 
over 30 minutes.
»  Monitor the person for respiratory depression.
If convulsions 
»  last for more than 30 minutes OR 
»  occur so frequently that the person does not recover 
consciousness between convulsions OR
»  are not responsive to two doses of diazepam 
SUSPECT STATUS 
EPILEPTICUS
ASSESSMENT AND MANAGEMENT IN EMERGENCY 
CASES SHOULD PROCEED SIMULTANEOUSLY!
2.  Are convulsions still 
continuing?
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»  Treat the medical condition
»  Antiepileptic maintenance 
treatment is not required.
»  Follow up after 3 months 
to assess if the person has 
epilepsy.
»  Follow up after 3 months.
»  In case of recurrent episodes, 
CONSULT A SPECIALIST. 
1.  Does the person have convulsive 
seizures?
2.  If convulsive seizures are present, 
do they have an acute cause?
Ask about the following criteria:
»  Loss of or impaired consciousness
»  Stiffness, rigidity lasting longer than 1 – 2 minute
»  Convulsive movements lasting longer than 1 – 2 minute
»  Tongue bite or self-injury
»  Incontinence of urine and / or faeces
»  After the abnormal movement: fatigue, drowsiness, sleepiness 
confusion, abnormal behavior, headache or muscles aches
Ask and look for: 
» Fever, headache, signs of meningeal irritation, e.g. stiff neck
»  If they started immediately after head injury
»  Metabolic abnormality (hypoglycaemia, hyponatraemia) 
»  Substance use or withdrawal
If person experiences 2 or fewer criteria 
suspect non-convulsive seizures or other medical 
condition.
If person experiences convulsive movements and 
2 other criteria, these could be convulsive seizures 
and could have an acute cause or be due to 
epilepsy.
Suspect an acute etiology
» Neuroinfection (meningitis / encephalitis) 
»  Cerebral malaria 
»  Head injury 
»  Hypoglycaemia or hyponatraemia 
»  Substance use / withdrawal 
IF YES and a child aged 6 months to 6 years 
with fever and seizures have one of the following 
3 criteria:
»  Focal – starts in one part of the body
»  Prolonged – more than 15 minutes 
»  Repetitive – more than 1 episode during 
the current illness
Suspect complex febrile 
seizure.
  Refer for hospital 
admission. 
»  Look for neuroinfection 
(suspect cerebral malaria in 
high endemic settings).
»  Follow up.
Suspect simple febrile seizure
»  Manage fever and look for 
its cause according to the 
local IMCI guidelines.
»  Observe for 24 hours.
»  Follow up.If none of the 3 criteria present in a febrile child
If no acute cause
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3.  Has the person had at least 2 
convulsive seizures in the last year 
on 2 different days? Not epilepsy
»  Maintenance of antiepileptic drugs is not 
required.
»  Follow up after 3 months. If there are additional 
abnormal movements suggestive of a seizure, 
assess for possible epilepsy.
If there is no clear cause and 
the person had a single convul-
sive seizure
Ask about: 
»  Severity: 
 –  How often do they occur?
 – How many did they have in the last year?
 – When was the last episode?
»  Possible etiology of the epilepsy (any history of birth 
asphyxia or trauma, head injury, infection of the brain, 
family history of seizures) »  Initiate antiepileptic drug  » EPI 2.1; either 
phenobarbital, phenytoin, carbamazepine or 
valproate. » EPI 2.3
»  Educate about condition, lifestyle and safety 
issues, and importance of adherence and 
regular follow-up. » EPI 3.1
»  Follow up regularly. » EPI 2.2
If yes, 
consider epilepsy
If no acute cause
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»  If available, consider carbamazepine or valproate 
» EPI 2.3 (avoid phenobarbital and phenytoin) 
»  Manage associated intellectual disability.  » DEV 
or behavioural disorder.  » BEH
»  Advise folate  (5 mg / day) in all women of child bearing age.
»  Avoid valproate in all women of child bearing age.  
» Avoid valproate in pregnant women.  
» Avoid polytherapy in pregnant women.  
» Advise delivery in a hospital.  
» At delivery, give 1 mg vitamin K i.m. to the newborn to 
prevent haemorrhagic disease of the newborn.
»  Initiate either phenobarbital, phenytoin, carbamazepine 
or valproate, or continue antiepileptic drug therapy if this 
has already started.
»  Manage both the epilepsy and the concurrent 
condition.  
4. Person in a special group
5.  Concurrent conditions
In children, look for presence of associated intellectual disability 
(see Developmental Disorders Module) » DEV or behavioural 
problems (see Behavioural Disorders Module) » BEH
Women of child bearing age
Consider possible presence of depression, psychosis or 
self-harm (see mhGAP-IG Master Chart)
If pregnant
If breastfeeding
If a concurrent 
condition is present 
If associated with 
intellectual disabil-
ity or behavioural 
disorders
Epilepsy / Seizures EPI 1
Assessment and Management Guide
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2.1  Initiate Antiepileptic Drug Therapy 
»  Prescribe phenobarbital, phenytoin, carbamazepine or 
valproate, based on country-specifi c availability.
»  Start treatment with only one antiepileptic drug.
»  Initiate treatment with the lowest dose and build up slowly 
until complete seizure control is obtained.
»  The aim of treatment is to achieve the lowest maintenance 
dose that provides complete seizure control. 
»  Tell person and family about:
 – the delay in onset of effect and the time course of treatment; 
 –  potential side-effects and the risk of these symptoms; to 
seek help promptly if these are distressing;
 –  the risk of abrupt discontinuation / withdrawal symptoms on 
missing doses;
 –  the need for regular follow-up.
»  Ask person and the family to keep a simple seizure diary.
»  For co-morbid medical conditions: Before prescribing anti-
epileptic drug, consider potential for drug-disease or drug-drug 
interaction. Consult the National or the WHO Formulary.
2.2 Follow-up 
»  Ask and look for symptom response, adverse effects and 
adherence.
»  The adverse effects could be because of high dose of the 
antiepileptic drug (such as drowsiness, nystagmus, diplopia 
and ataxia) or these could be idiosyncratic effects (such as 
allergic reactions, bone marrow depression, hepatic failure). 
For details of individual antiepileptic drugs, see » EPI 2.3
»  The correct antiepileptic drug dose is the smallest one at 
which complete seizure control is achieved without adverse 
effects.
»  If there are dose-determined adverse effects, decrease the 
dose of the medication. In case of idiosyncratic reactions, 
stop the antiepileptic drug the person is on and switch to any 
of the other antiepileptic drugs.
»  If response is poor (less than 50% reduction in frequency 
of seizures) despite good adherence, increase to maximum 
tolerated dose.
»  If response still poor, try monotherapy with another drug. 
Start the second drug and build up to an adequate or 
maximum-tolerated dose and only then taper slowly off the 
fi rst drug.
»  If seizures are very infrequent and higher doses of 
medications produce side-effects, less than complete 
seizure freedom may be the goal.
»  If seizures continue after attempts with two mono-therapies, 
review diagnosis (including co-morbidity), treatment adher-
ence and, if necessary, consult a specialist for further assess-
ment and treatment.
»  If there are adverse effects or response is poor, follow up 
monthly.
»  Continue to meet every 3 months if seizures are well 
controlled.
How and when to stop antiepileptic drugs 
»  No seizures within the last 2 years.
»  Discuss decision with person / carer, weighing up the risk 
of the seizures starting again.
»  In some cases of epilepsy, long-term antiepileptic drug 
therapy might be required, e.g. in cases of epilepsy 
secondary to head trauma or neuroinfections, or if the 
seizures were diffi cult to control.
»  Reduce treatment gradually over 2 months.
 Pharmacological Treatment and Advice
The vast majority of seizures can be controlled 
(stopped or signiﬁ cantly reduced) by antiepileptic 
drugs.
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Phenobarbital
»  Only needs to be given once a day.
»  Give at bedtime (reduces drowsiness during the day).
  Adults: Initiate with 1 mg / kg / day (60 mg tablet) for 2 weeks. If 
poor response, increase to 2 mg / kg / day (120 mg) for 2 months. 
If seizures persist, increase the dose to 3 mg / kg / day (180 mg).
  Children: Initiate with 2 mg / kg / day for 2 weeks. If poor response 
increase the dose to 3 mg / kg / day for 2 months. If seizures 
persist, increase the dose to maximum of 6 mg / kg / day.
»  Continuous administration for 14 – 21 days is needed to obtain 
steady levels of phenobarbital in the blood; therefore occur-
rence of seizures during this period should not be considered 
as treatment failures.
»  Side-effects: Dose-determined: drowsiness, lethargy, and  
hyperactivity in children; idiosyncratic: skin rash, bone marrow 
depression, hepatic failure.
Carbamazepine
»  Give the medication twice daily. 
»  Steady state is reached in up to 8 days.
»  Side effects: allergic skin reactions (which can be severe); 
blurred vision, diplopia (double vision), ataxia (staggering 
gait) and nausea: the latter symptoms are usually seen at  
the start of treatment or at high doses.
Phenytoin
»  In children , give twice daily; in adults , it can be given 
once daily.
»  Small dose increments may lead to big changes in concentra-
tion, therefore, increments should be by 25 – 30 mg. 
»  Dose related: drowsiness, ataxia and slurred speech, motor 
twitching and mental confusion, coarsening of facial features, 
gum hyperplasia and hirsutism (uncommon); idiosyncratic: 
anaemia and other haematological abnormalities, hypersensi-
tivity reactions including skin rash, hepatitis.
Sodium valproate
»  Different preparations are available; usually given 2 or 3  
times daily.
»  Side-effects: sedation and tremor (dose-determined), 
transient hair loss (re-growth normally begins within 6 
months), increase in body weight, impaired hepatic  
function (idiosyncratic).
 2.3 Pharmacological Treatment and Advice
Child Adolescent / adult
Starting dose Maintenance dose Starting dose Maintenance dose
Carbamazepine 5 mg / kg / day 10 – 30 mg / kg / day 100 – 200 mg / day 400 – 1400 mg / day
Phenobarbital 2 – 3 mg / kg / day 2 – 6 mg / kg / day 60 mg / day 60 – 180 mg / day
Phenytoin 3 – 4 mg / kg / day
3 – 8 mg / kg / day (maxi-
mum 300 mg daily)
150 – 200 mg / day 200 – 400 mg / day
Sodium valproate 15 – 20 mg / kg / day 15 – 30 mg / kg / day 400 mg / day 400 – 2000 mg / day
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3.1  Provide education to people with  
seizures / epilepsy and carers 
 
Explain:
»  What is a seizure / epilepsy (e.g. “A seizure or fit is a problem 
related to the brain. Epilepsy is an illness involving recurrent 
seizures. Epilepsy is not a contagious disease and is not 
caused by witchcraft or spirits”).
»  The nature of the person’s seizure and its possible cause.
»  That it is a chronic condition, but seizures can be fully 
controlled in 75 % of individuals, after which they may live 
without medication for the rest of their lives.
»  Different treatment options.
»  Reasons for referral (when applicable).
 Precautions to be taken at home during seizures:
»  Lay the person down, on their side, with their head turned 
to the side to help with the breathing and prevent aspirating 
secretions and vomit.
»  Make sure that the person is breathing properly.
»  Do not try to restrain or put anything in the person’s mouth.
»  Stay with the person until the seizure stops and they wake up.
»  Sometimes people with epilepsy know or feel that the seizures 
are coming. In that case they should lie down somewhere 
safe to protect themselves from falling.
»  Remember that epilepsy is not contagious, so no one will 
catch seizures by helping.
Explore lifestyle issues:
»  People with epilepsy can lead normal lives. They can marry 
and have children. 
»  Parents should never remove children with epilepsy from 
school. 
»  People with epilepsy can work in most jobs. However they 
should avoid certain jobs such as working with or near heavy 
machinery. 
»  People with epilepsy should avoid cooking on open fires  
and swimming alone. 
»  People with epilepsy should avoid excessive alcohol and any 
recreational substances, sleeping much less than usual or  
going to places where there are flashing lights.
»  National laws related to the issue of driving and epilepsy  
need to be observed.
 Psychosocial treatment and advice 
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Developmental disorder is an umbrella term covering disorders such as 
intellectual disability / mental retardation as well as pervasive developmental 
disorders including autism. These disorders usually have a childhood 
onset, impairment or delay in functions related to central nervous system 
maturation, and a steady course rather than the remissions and relapses 
that tend to characterize many other mental disorders. Despite a childhood 
onset, the developmental disorders tend to persist into adulthood. People 
with developmental disorders are more vulnerable to physical illness and to 
develop other priority conditions mentioned in the mhGAP-IG and require 
additional attention by health-care providers.
Intellectual disability
Intellectual disability is characterized by impairment of skills across multiple 
developmental areas (i.e., cognitive, language, motor and social) during the 
developmental period. Lower intelligence diminishes the ability to adapt  
to the daily demands of life. Intelligence Quotient (IQ) tests can provide 
guidance to the person’s abilities, but should be used only if the tests have 
been validated for use in the population in which they are being applied.
Pervasive developmental disorders including autism
The features are impaired social behaviour, communication and language, 
and a narrow range of interests and activities that are both unique to the 
individual and carried out repetitively. They originate in infancy or early 
childhood. Usually, but not always, there is some degree of intellectual 
disability. Behaviours mentioned above are often seen in individuals with 
intellectual disabilities as well.
wire possition
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»  Start family psychoeducation. » DEV 2.1
»  Consider parent skills training, when available. » INT
»  Inform about available educational and social  
services and collaborate with them.
»  Contact person’s school after receiving person and  
carer consent and provide advice. » DEV 2.2
»  Assess current level of adaptive functioning in  
consultation with specialist,  if available.
»  Manage associated conditions such as visual and hearing 
impairment
»  Provide support for anticipated difficult situations in life.
»  Facilitate and collaborate with community-based  
rehabilitation services. » DEV 2.3
»  Help promote and protect the human rights of the child 
and the family » DEV 2.4
»  Provide support for carers » DEV 2.5
»  Refer to a specialist, if available, for further etiological 
assessment. 
»  Follow up regularly. » DEV 2.6
»  Manage nutrition problems, including iodine deficiency 
and medical conditions, using IMCI guidelines.
If there is a delay in  
development or the  
mentioned oddities in 
communication or  
behaviour 
Are there any nutritional 
deficiencies including iodine 
deficiency and / or medical 
conditions? 
1.  Does the child have a delay  
in development? 
Assess child’s development using local developmental  
milestones or comparing the child with other children  
of the same age in the same country. 
(For example determine the age at which the child started smiling,  
sitting up, standing up alone, walking, talking, understanding  
instructions, and communicating with others.) 
For older children in addition to the above, note how they are  
managing school work or everyday household activities.
Look for: 
»  Oddities in communication (e.g. lack of social usage of the  
language skills, lack of flexibility in language usage)
»  Restricted, repetitive (stereotyped) patterns of behaviour,  
interests, and activities
»  The time, sequence and course of these features
»  Loss of previously acquired skills
»  Family history of developmental disorder
»  Presence of visual and hearing impairment
»  Associated epilepsy
»  Associated signs of motor impairment or cerebral palsy
IN ALL CASES
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2.  Is the delay in development due 
to non-stimulating environment or 
maternal depression? 
»  Provide family psychoeducation » DEV 2.1 
and train parents on how to provide a stimulating 
environment for the child.
»  Treat maternal depression. See Depression Module » DEP 
and other WHO documents for maternal depression and 
early childhood development. 
If non-stimulating environment 
or mother with depression
3.  Look for another priority mental, 
neurological, or substance use 
disorder (see mhGAP-IG Master Chart).
Consider especially:
»  Epilepsy 
»  Depression 
»  Behavioural disorders
If YES »  Treat according to relevant modules
 – Epilepsy » EPI
 – Depression » DEP
 – Behavioural disorders » BEH
4.  Does the child have problem 
behaviours?
If YES »  Manage any underlying treatable acute physical problem 
exacerbating behavioural problems.
»  Consider additional family psychoeducation (See 
Behavioural Disorders Module)  » BEH and parent skills 
training for the specifi c problem behaviour. » INT
»  Consider cognitive behavioural therapy (CBT), if trained 
resources are available » INT
»  Provide further support for carers » DEV 2.5
  Use care when prescribing psychotropic medication to 
people with developmental disorders as they are often 
more sensitive to their side-effects.
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2.1  Family psychoeducation 
Psychoeducation involves the person with developmental disorder 
and the family, depending on the severity of the condition and 
availability and significance of the family member role in daily life. 
Parent or significant family member needs to be trained to:
»  Accept and care for the child with developmental disorder.
»  Learn what is stressful to the child and what makes them happy; 
what causes their problem behaviours and what prevents 
them; what are the child’s strengths and weaknesses and how 
best they learn. 
»  Understand that people with developmental disorders may 
have difficulties when they face new situations.
»  Schedule the day in terms of regular times for eating, playing, 
learning and sleeping.
»  Involve them in everyday life, starting with simple tasks one at 
a time.
»  Keep them in schools as far as possible; attending mainstream 
schools even if it is part time is preferable.
»  Be careful about their general hygiene and train them in  
self-care.
»  Reward their good behaviour after the act and give no reward 
when the behaviour is problematic. » BEH 2.1
»  Protect them from abuse.
»  Respect their right to have a safety zone within a visible 
boundary where they can feel safe, comfortable and move 
around and play freely the way they like.
»  Communicate and share information with other parents who 
have children with similar conditions.
2.2  Advice to teachers
»  Make a plan on how to address the child’s special  
educational needs. Simple tips include:  
 
– Ask the child to sit at the front of the class. 
– Give the child extra time to understand assignments.  
– Break long assignments into smaller pieces. 
– Look for bullying and take appropriate action to stop it.
2.3  Community-based rehabilitation (CBR)
CBR focuses on involving the communities in enhancing the  
quality of life for people with disabilities and their families,  
meeting basic needs and ensuring social integration and partici-
pation. CBR gives people with disabilities access to rehabilitation 
in their own communities using predominantly local resources. 
It is carried out in homes, schools and other central places in the 
community. It is implemented through the combined efforts of 
children with developmental disorders, their families and com-
munities, and appropriate health, educational, vocational and 
social services. It involves promoting a climate that respects and  
protects the rights of people with disabilities, training the child, 
empowering families, helping to reduce stress, and improve  
coping with the developmental disorder. Interventions may 
range from activities of daily living, school referral, vocational 
training and parental support.
2.4  Promoting and protecting the human 
rights of the child and the family
»  Review the general principles of care. Be vigilant about issues 
of human rights and dignity. For example:  
 –  Do not start interventions without informed consent;  
prevent maltreatment. 
 –  Avoid institutionalization.
 –  Promote access to schooling and other forms of education.
2.5  Support for carers
»  Identify psychosocial impact on carers. 
»  Assess the carer’s needs and promote necessary support  
and resources for their family life, employment, social activities 
and health. Arrange for respite care, which means a break 
now and then when other trustworthy caregivers take over 
temporarily.
Intervention Details
DEV 2
 Psychosocial treatment and advice
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2.6 Follow-up
»  Follow up regularly.
»  For early childhood use IMCI guidelines for follow-up. 
»  Referral criteria: 
 –  if you notice no improvement or further deterioration in development 
and / or behaviour;
 – if you predict danger to the child or others;
 – if physical health is affected (such as nutrition problems).
Where to refer
»  If the person (a) meets the above referral criteria and (b) has symptoms 
consistent with intellectual disability, characterized by general delay 
across multiple developmental areas, such as cognitive, language, motor 
and social, then:
 –  Avoid institutionalized care.
 –  Refer to outpatient intellectual disability specialized services, if 
available. 
 –  Refer to outpatient speech / language therapy services, if available. 
»  If the person (a) meets the above referral criteria and has (b) symptoms 
consistent with a pervasive developmental disorder, characterized by 
problems in social interaction, communication and behaviour (restricted /
repetitive), then:
 –  Avoid institutionalized care.
 –  Refer to outpatient specialized services for pervasive developmental 
disorders or autism if available.
Intervention Details
DEV 2
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Prevention of Developmental Disorders 
»  Provide care, prevent and treat malnutrition and infection in pregnant women. Provide safe delivery and care for 
the newborn after delivery. Prevent head injury, neuroinfections and malnutrition in infants and young children. 
»  Identify the poorly nourished and frequently ill and other groups of children who are at risk and provide care. 
Arrange meetings with parents or visit their homes.
»  Train parents on how to improve mother-infant interactions and how to provide psychosocial stimulation to the child. 
»  In case you fi nd that the mother has depression, start treatment of the mother preferably through psychosocial 
interventions. 
»  Offer additional psychosocial support to mothers with depression or with any other mental, neurological or 
substance use condition. This may include home visiting, psychoeducation, improving mothers’ knowledge on child 
rearing practices.
»  Women who are pregnant, or planning to become pregnant, should consider avoiding any alcohol consumption, as 
the developing brain is particularly sensitive to the effects of alcohol, even in the fi rst few weeks post-conception.
Further WHO resources:
»  IMCI : http://www.who.int/child_adolescent_health/topics/prevention_care/child/imci/en/index.html
» Making Pregnancy Safer: http://www.who.int/making_pregnancy_safer/en/
»  Prevention of mental disorders: http://www.who.int/mental_health/evidence/en/prevention_of_mental_disorders_sr.pdf
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Hyperkinetic disorder / attention deficit hyperactivity  
disorder (ADHD) 
The main features are impaired attention and overactivity. Impaired attention 
shows itself as breaking off from tasks and leaving activities unfinished. The 
child or adolescent shifts frequently from one activity to another. These 
deficits in persistence and attention should be diagnosed as a disorder only if 
they are excessive for the child or adolescent’s age and intelligence, anwd 
affect their normal functioning and learning. Overactivity implies excessive 
restlessness, especially in situations requiring relative calm. It may involve the 
child or adolescent running and jumping around, getting up from a seat 
when he or she was supposed to remain seated, excessive talkativeness and 
noisiness, or fidgeting and wriggling. The characteristic behavioural problems 
should be of early onset (before age 6 years) and long duration (> 6 months), 
and not limited to only one setting.
Other behavioural disorders 
Unusually frequent and severe temper tantrums and persistent severe 
disobedience may be present. Disorders of conduct may be characterized  
by a repetitive and persistent pattern of dissocial, aggressive or defiant 
conduct. Such behaviour, when at its most extreme for the individual, 
should be much more severe than ordinary childish mischief or adolescent 
rebelliousness. Examples of the behaviours may include: excessive levels of 
fighting or bullying; cruelty to animals or other people; fire-setting; severe 
destructiveness to property; stealing; repeated lying and running away from 
school or home. Judgements concerning the presence of other behavioural 
disorders should take into account the child or adolescent’s developmental 
level and duration of problem behaviours (at least 6 months).
  
 
“Behavioural disorders” is an umbrella term that includes more specific 
disorders, such as hyperkinetic disorder or attention deficit hyperactivity 
disorder (ADHD) or other behavioural disorders. Behavioural symptoms  
of varying levels of severity are very common in the population. Only 
children and adolescents with a moderate to severe degree of psycho-
logical, social, educational or occupational impairment in multiple  
settings should be diagnosed as having behavioural disorders. For some 
children with behavioural disorders, the problem persists into adulthood.
wire possition
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»  Provide family psychoeducation. » BEH 2.1 
»  Consider parent skills training, when available. » INT
»  Contact the person’s teacher (if the person goes to school 
and consent is given by the person and carer), provide 
advice and plan for special educational needs. » BEH 2.2
»  Consider psychosocial interventions such as cognitive 
behavioural therapy (CBT) and social skills training based 
on availability. » INT
»  Support family to handle social and familial problems 
affecting child’s behaviour. When available, use problem-
solving techniques. » INT 
»  Assess carers regarding the impact of behavioural 
disorders and offer them support for their personal, social 
and mental health needs. » BEH 2.3 
»  If the carer has depression, use the relevant module of 
mhGAP-IG. » DEP  
»  CONSULT A SPECIALIST  for methylphenidate » BEH 3 
only if the:
 –  above interventions fail
 –  child has been carefully assessed 
 –  child is at least 6 years old. 
»  Methylphenidate should NOT be used if child is 
younger than 6.  
»  Monitor side-effects and potential for misuse and diversion. 
»  Record prescription details and side-effects regularly and 
carefully in the case notes.
If several symptoms are 
present and
»  Persist in multiple settings
»  Exceed those of other 
children of the same age 
and intelligence level
»  Started before age 6
»  Lasted at least 6 months
»  Cause signifi cant disruption 
in child functioning
consider Attention Deﬁ cit 
Hyperactivity Disorder 
(ADHD)
RULE OUT: 
»  Medical conditions or 
other priority conditions 
that can potentially cause 
behavioural disorders (e.g. 
hyperthyroidism, 
depression or alcohol or 
drug use)
1.  Does the person have problems with 
inattention and overactivity?
Ask person and carer about:
»  Inattention
»  Premature breaking off from tasks
»  Leaving tasks unfi nished
»  Frequent changing from activity to activity
» Hyperkinesis:
 –  Over-activity (excessive for the context or situation)
 –  Diffi culty sitting still
 –  Excessive talking or noisiness
 –  Fidgeting or wriggling
»  Age of onset, and persistence in different settings: They may have 
trouble with parents, teachers, siblings, peers, or in all domains of 
function. If the problems are only in one domain consider causes 
specifi c to that domain.
»  Assess if the symptoms are appropriate for the child’s 
developmental level.
»  Explore the impact of:
 –  Social, familial and educational or occupational factors
 –  Medical problems
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2.  Does the person show evidence of 
other behavioural disorders?
»  Provide family psychoeducation. » BEH 2.1 
»  Consider parent skills training, when available. » INT
»  Contact person’s teacher (if person goes to school and 
consent is given by the person and carer), provide advice 
and plan for special educational needs. » BEH 2.2
»  Anticipate major life changes (such as puberty, starting 
school, or birth of a sibling) and arrange personal and 
social support. 
»  Consider psychosocial interventions such as CBT and 
social skills training based on availability. » INT
»  Assess carers regarding the impact of behavioural 
disorders and offer them support for their personal, social 
and mental health needs. » BEH 2.3.
»  DO NOT use medicines for behavioural disorders in 
children and adolescents.  Consider methylphenidate 
only under conditions mentioned above for hyperkinetic 
disorder.If several symptoms are 
present and
»  are much more severe than 
ordinary childish mischief or 
adolescent rebelliousness
»  have lasted at least 6 
months
»  are inappropriate for the 
child’s developmental level
»  are not only in response to 
severe social, family or 
educational stressors 
consider a diagnosis of 
other behavioural disorders
Ask about:
»  Repeated and persistent dissocial, aggressive, or defi ant conduct, e.g. 
 – Excessive levels of fi ghting or bullying 
 –  Cruelty to animals or other people 
 –  Severe destructiveness to property 
 –  Fire-setting 
 –  Stealing 
 –  Repeated lying 
 –  Truancy from school 
 –  Running away from home
 –  Frequent and severe temper tantrums 
 –  Defi ant provocative behaviour 
 –  Persistent severe disobedience
»  The age of onset of symptoms and the duration
Assess if the symptoms are appropriate for the child’s 
developmental level.
Explore the impact of:
»  Social, familial and educational or occupational factors 
»  Medical problems
»  Alcohol or drug use
RULE OUT: 
»  Medical conditions or 
other priority conditions 
that can potentially cause 
behavioural disorders (e.g. 
hyperthyroidism, depression 
or alcohol or drug use)
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3.  Is the person’s problem behaviour a  
reaction to fear or trauma?
4.  Does the person have any other  
priority conditions?  
(see mhGAP-IG Master Chart)
Explore:
»  Is the child being bullied or harmed outside the home?
»  Is there any concern about injury or threat within the home?
»  Do the parents have any priority conditions for which they require 
services? (see mhGAP-IG Master Chart)
Look for the presence of:
»  Developmental disorders
»  Depression
»  Alcohol or drug use
»  Epilepsy
»  Psychosis
»  Suicidal behaviour
If YES
If YES
»  Consult with parents. 
»  Provide parent education and home visits. In case of  
serious risk or non-response, involve other available 
resources and specialists.
»  Consider legal interventions according to local  
legislation.
»  Provide advice and offer services to those parents who 
need mental health services and consent to receive them. 
Manage the concurrent condition according to the  
appropriate module for that disorder:
»  Developmental Disorders » DEV
»  Depression » DEP
»  Alcohol Use Disorders » ALC
»  Drug Use Disorders » DRU
»  Epilepsy » EPI
»  Psychosis » PSY
»  Suicide / Self-harm » SUI
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2.1  Family psychoeducation
»  Accept and care for the child with a behavioural disorder.
»  Be consistent about what the child is allowed and not  
allowed to do.
»  Praise or reward the child after you observe good behaviour 
and respond only to most important problem behaviours; find 
ways to avoid severe confrontations or foreseeable difficult 
situations.
»  Start behavioural change by focusing on a few very observable 
behaviours that you think the child can do.
»  Give clear, simple and short commands that emphasize what 
the child should do rather than not do.
»  Never physically or emotionally abuse the child. Make 
punishment mild and infrequent compared to praise. For 
example, withhold rewards (e.g. treats or fun activities)  
after a child does not behave properly.
»  As a replacement for punishment, use short and clear-cut 
“time out” after the child shows problem behaviour. “Time 
out” is temporary separation from a rewarding environment, 
as part of a planned and recorded programme to modify  
behaviour. Brief the parents how to apply it when required. 
»  Put off discussions with the child until you are calm.
2.2 Advice to teachers
Make a plan on how to address the child’s special  
educational needs. Simple tips include:
»  Ask the child to sit at the front of the class.
»  Give the child extra time to understand assignments. 
»  Break long assignments into smaller pieces.
»  Look for bullying and take appropriate action to stop it. 
2.3  Support for carers
»  Identify psychosocial impact on carers. 
»  Assess the carer’s needs and promote necessary support and 
resources for their family life, employment, social activities and 
health. Arrange for respite care, which means a break now and 
then when other trustable caregivers take over temporarily.
 Psychosocial interventions
Intervention Details
BEH 2
47
Behavioural Disorders
»  DO NOT use medication in primary care without  
consulting a specialist. 
»  DO NOT use medicines for general behavioural disorders  
in children and adolescents.  Consider methylphenidate for 
hyperkinetic disorder only if psychosocial interventions have 
failed, child has been carefully assessed and is at least 6 years 
old, and conditions whose management can be complicated 
by methylphenidate have been ruled out.
»  Use of stimulant medication must always be part of a 
comprehensive treatment plan that includes psychological, 
behavioural and educational interventions.
»  Record the quantity dispensed and date of prescription, as well 
as response and side effects regularly in the medical record. 
Methylphenidate
3.1  Initiating methylphenidate treatment
»  Availability: Methylphenidate is restricted in many countries. 
Know the legislation governing the prescription and supply of 
stimulants.
»  Preparation: Immediate-release formulations are usually 
available as a 10 mg tablet. Modified-release formulations are 
available in some countries.
»  Pre-medication assessment for use of methylphenidate: 
In addition to the suggestions for assessment given in the 
flowchart, specifically assess:
 –  cardiovascular system – history, pulse, blood pressure, 
cardiac examination (obtain ECG if it is clinically indicated); 
methylphenidate is contraindicated in cardiovascular diseases;
 –  height and weight;
 –  risk assessment for substance use and drug diversion;
 –  specific medical diseases (e.g. use methylphenidate with 
caution in children with both ADHD and epilepsy); 
 –  other mental disorders – methylphenidate may worsen  
anxiety and is contraindicated in psychosis. 
»  DO NOT prescribe without supervision of specialist. 
3.2  Dosage and administration
»  Immediate release formulation:
 – Start at 5 mg once or twice daily. 
 –  Gradually (over 4 – 6 weeks) increase the dose (in 2 – 3 divided 
doses) until there is no further improvement and side-effects 
are tolerable, up to a maximum recommended daily dose of 
60 mg (in 2 – 3 divided doses).
»  Extended-release preparations: If available, prescribe as a 
single dose in the morning. 
3.3 Assessing response 
Record symptoms and side-effects at each dose change. If 
rebound hyperactivity occurs when the effect of the drug wears 
off, the doses can be divided to include a late evening dose. 
3.4 Side-effects
»  Common side-effects: insomnia, decreased appetite,  
anxiety and mood changes 
 –  reduce dose and CONSULT A SPECIALIST.  
»  Less common side-effects: abdominal pain, headache, 
nausea, temporary growth retardation and low weight 
(monitor height and weight, consider a break in drug 
treatment over school holidays to allow ‘catch-up’ growth), 
change in blood pressure and heart rate (monitor before and 
after dose change and once in 3 months thereafter – consult 
a physician if sustained change over two recordings is seen), 
vomiting (give with food), tics.
»  Routine blood tests and ECG are not required; they should be 
conducted if there is a clinical indication.
3.5 Follow-up 
»  Discontinue methylphenidate if there is no response  
after 1 month. 
»  Measure weight every 3 months and height every  
6 months. If increase in height or weight stops, discontinue 
methylphenidate and consult a specialist.  
»  If the child responds to methylphenidate, continue it for one 
year and then consult a specialist  to check whether 
further continuation is justified.
 Pharmacological interventions: Methylphenidate
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Dementia DEM
Dementia is a syndrome due to illness of the brain, which is 
usually chronic and progressive in nature. The conditions that 
cause dementia produce changes in a person’s mental ability, 
personality and behaviour. People with dementia commonly 
experience problems with memory and the skills needed to 
carry out everyday activities. Dementia is not part of normal 
ageing. Although it can occur at any age, it’s more common in 
older people. 
People with dementia often present with complaints of  
forgetfulness or feeling depressed. Other common symptoms 
include deterioration in emotional control, social behaviour  
or motivation. People with dementia may be totally unaware 
of these changes and may not seek help. Sometimes it  
is thus the family who seeks care. Family members may 
notice memory problems, change in personality or behaviour, 
confusion, wandering or incontinence. However some people 
with dementia and their carers may deny or minimize the 
severity of memory loss and associated problems. 
Dementia results in decline in intellectual functioning 
and usually interferes with activities of daily living, such 
as washing, dressing, eating, personal hygiene and toilet 
activities.
wire possition
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»  Convey the result of the assessment. » DEM 3.1
»  Offer psychosocial treatments for cognitive symptoms 
and functioning. » DEM 3.2 
»  Promote independence and maintain function.  
» DEM 3.3
»  Follow up. » DEM 3.6
» Consult a spECialist.
» Consult a spECialist.
If on testing, cognitive 
impairment or memory 
complaint:
»  has been present for at least 
6 months
»  is progressive in nature, and
»  is associated with impairment 
of social function
Dementia is likely 
if there are any other unusual fEaturEs,  
such as:
»  Onset before the age of 60 years
»  Clinical hypothyroidism
»  Cardiovascular disease
»  History of previous STI or HIV 
»  History of head injury or stroke 
»  if the onset is abrupt and duration is short  
(days to weeks)
»  if the disturbance is more at night and is  
associated with impairment of consciousness 
»  if there is disorientation to time / place
Delirium is likely 
1.  Does the person have dementia? 
»  Ask the person, and also someone who knows them well, about 
problems with memory, orientation, speech and language, and  
difficulties in performing key roles and activities.
»  Test orientation, memory and language. » DEM 2
»  Ask the person or carer about the symptoms:
 –  When were they first noticed?
 –  What was the age of the person?
 –  Was the onset sudden or gradual (over several months or years)?
 –  What is the duration of the illness?
 –  Are the symptoms worse at night ?
 –  Is there associated drowsiness, impairment of consciousness?
 –  Was the onset linked to a head injury, a blackout or a stroke?
»  Is there a clinical history of:
 –  Goitre, slow pulse, dry skin or hypothyroidism?
 –  Sexually transmitted infection (STI) or HIV?
 –  Cardiovascular disease?
 –  Poor dietary intake, malnutrition, anaemia?
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2.  Does the person have another 
priority mental disorder?
3.  Does the person have behavioural and 
psychological symptoms of dementia?
»  Moderate to severe depression
 notE: Depression is common in dementia, but symptoms may be 
difﬁ cult to elicit from the person, so it may be necessary to rely on 
the carer’s report of signiﬁ cant recent change.
»  psychosis
(Assess according to mhGAP-IG Master Chart.)
ask the carer about: 
»  Behaviour: wandering, night-time disturbance, agitation and aggression 
»  Psychological symptoms: hallucinations, delusions, anxiety or depressed mood 
»  When these symptoms occur and how often
»  Whether these symptoms create a problem for the person or carer
Explore possible precipitants:
»  Physical, such as pain, constipation, urinary infection
»  Psychological, such as depression
»  Environmental, such as crowding or any relocation
 look for imminent risk of harm to the person (e.g. from wandering) or 
carer (e.g. from assaultive behaviour that frightens the carer or has hurt others)
»  Manage the associated moderate-severe 
depression » DEp or psychosis. » psY
»  Review dementia diagnosis after successful treatment of 
depression. Cognitive impairment may be the result 
of severe depression, rather than dementia. Full recovery 
would indicate possibility of depression as the primary 
problem.
»  Manage with psychosocial therapies. » DEM 3.4
»  Follow up. » DEM 3.6
»  provide psychosocial therapies. » DEM 3.4
»  In addition, offer pharmacological 
interventions.  » DEM 4
If moderate to severe 
depression is present
If psychosis is present
If behavioural and 
psychological symptoms 
are present
If imminent risk of harm to 
person or carer
51
4.  Are cardiovascular disease and risk 
factors present?
5.  Does the person suffer from other 
physical conditions?
6.  Is the carer experiencing strain or  
in need of support?
assess for
»  Hypertension (blood pressure)
»  Hyperlipidaemia
»  Diabetes
»  Smoking 
»  Obesity (weight, waist-to-hip ratio)
»  Heart disease (angina or myocardial infarction)
»  Previous stroke or transient ischaemic attacks
»  Evaluate nutrition, eyesight, hearing, dentition, bladder and  
bowel function, and pain
»  Obtain urinalysis
»  Review medications, particularly those with significant anticholin-
ergic side-effects (such as amitriptyline (an antidepressant); many 
antihistamines; antipsychotic drugs)
assess
»  Who is the main carer?
»  Who else provides care and what care do they provide?
»  Is there anything they find particularly difficult to manage?
»  Are the carers coping? Are they experiencing strain? Are  
they depressed?
»  Are they facing loss of income and / or additional expenses  
because of the needs for care?
If cardiovascular risk factors 
or disease are present
if associated physical condi-
tions are present, especially: 
» Poor nutritional status 
»  Urinary tract infection
»  Constipation or diarrhoea
»  Medication interactions or 
side-effects
if carer is:
»  Experiencing strain
»  Depressed
»  Facing overwhelming  
treatment costs
»  Reduce cardiovascular risk factors according to  
local guidelines:
 –  Advise person to stop smoking
 –  Treat hypertension
 –  Advise weight-reducing diet for obesity
 –  Treat diabetes
»  Refer to appropriate specialists. 
»  Provide interventions for carers. » DEM 3.5
»  Explore psychosocial interventions:
 –  financial support such as disability services
 –  information about the condition of the person
 –  respite care 
 –  activation of community support network
 –  family or individual therapy if available
»  Follow up. » DEM 3.6
»  Assess carer depression according to Depression Module 
and manage accordingly.  » DEp
»  Treat associated physical conditions as it might  
improve cognition.
»  Refer to appropriate specialists. 
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identifying dementia requires: 
»  Assessment of memory and cognitive functioning using  
simple tests  
 
anD
»  Confirmation by interviewing a family member or other person 
who knows the person well that these problems:
 –  Developed fairly recently
 –  Have been getting worse AND
 –  Are causing regular difficulties in carrying out daily work, 
domestic or social activities
Dementia can also be assessed using any locally validated tool.
2.1  Assess memory and cognitive  
functioning
»  Assess memory by asking the person to repeat three common 
words immediately, then again 3 – 5 minutes later. 
»  Assess orientation to time (time of day, day of week, season 
and year), and place (where is the person being tested, or 
where is the nearest market or store to their home). 
»  Test language skills by asking the person to name parts of the 
body, and explaining the function of an item, such as, “What 
do you do with a hammer?”
2.2  Interview key informant
»  In an interview with a key informant (someone who knows  
the person well), ask about recent changes in thinking and 
reasoning, memory and orientation. Occasional memory 
lapses are common in older people, whereas some problems 
can be significant even if infrequent. 
»  Ask, for example, whether the person often forgets where 
they put things. Do they sometimes forget what happened  
the day before? Does the person sometimes forget where  
they are? 
»  Ask the informant when these problems started and whether 
they have been getting worse over time. Are there any time 
periods, lasting days, weeks or longer, when thinking and 
memory are completely back to normal?
»  Identifying problems with daily activities can be difficult if the 
family minimizes these problems, if the problems are relatively 
minor, or if families routinely provide extensive support and care 
for older people. More complex tasks such as managing a house- 
hold budget, shopping or cooking tend to be affected first.
Core self-care activities such as dressing, washing, feeding and 
toileting are only affected later.
»  You will need to know the “usual activities” for older people in 
your area and for this particular family. Explore whether there 
have been any recent progressive changes. Does the person 
make errors or take longer to carry out tasks, perform them 
less well, or give up activities?
Identifying Dementia
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3.1  Conveying the results of the assessment
Ask people who are assessed for possible dementia whether they 
wish to know the diagnosis and with whom it should be shared. 
The explanation should be tailored to their ability to understand 
and retain information.
Start with giving basic information – but do not overload with 
too much information. Consider saying:
»  Dementia is an illness of the brain and tends to get worse over 
time. 
»  Although there is no cure, there is much that can be done to 
help and support the person and the family.
»  Many specific concerns and behaviours can be managed  
as they arise. A lot can be done to make the person more 
comfortable and to make life less stressful for the carer.
Make a realistic offer of ongoing help and support, and inform 
the person and carer of any other support available in their  
community.
3.2  Psychosocial interventions for cognitive 
symptoms and functioning
»  Provide regular orientation information (e.g. day, date, weath-
er, time and names of people) to people with dementia to help 
them to remain oriented to time, place and person.
»  Use materials such as newspapers, radio or TV programmes, 
family albums and household items to promote communica-
tion, to orient them to current events, to stimulate memories 
and to enable people to share and value their experiences.
»  Use simple short sentences to make verbal communication 
clear. Try to minimize competing noises, such as the radio, TV, 
or other people’s conversation. Listen carefully to what the 
person has to say.
»  Keep things simple, avoid changes to routine and avoid expos-
ing the person to unfamiliar and bewildering places unless this 
is necessary.
3.3  Promote independence, functioning  
and mobility
Plan for activities of daily living in a way that maximizes inde-
pendent activity, enhances function, helps to adapt and develop 
skills, and minimizes need for support. Facilitate rehabilitation in 
the community involving people and their carers in planning and 
implementation of these interventions. Assist in liaison with avail-
able social resources.
Specifically consider the following:
»  Give advice to maintain independent toileting skills, includ-
ing prompting and regulation of fluid intake (if incontinence 
occurs, all possible causes should be assessed and treatment 
options tried before concluding it is permanent).
»  Inform family members that it is important to keep the floor 
of the person’s home without clutter as to reduce the risk of 
falling.
»  Recommend making adaptations in the person’s home. It can 
be helpful to add hand-rails or ramps. Signs for key locations 
(e.g. toilet, bath, bedroom) can help to ensure that the person 
does not get lost or lose orientation while at home.
»  Recommend physical activity and exercise to maintain mobility 
and to reduce the risk of falls.
»  Advise recreational activities (tailored to the stage of dementia).
»  Refer to occupational therapy, if available.
»  Manage sensory deficits (such as low vision, poor hearing) 
with appropriate devices (e.g. magnifying glass, hearing aids).
 Psychosocial interventions
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3.4  Managing behavioural and  
psychological symptoms
»  Identify and treat underlying physical health problems that 
may affect behaviour (pain, infections, etc).
»  Consider environmental modifications, such as appropriate 
seating, safe wandering areas, signs (e.g. no exit sign on 
street door, or signpost to toilet).
»  Identify events (e.g. shopping at a busy market) or factors 
(e.g. going out alone) which may precede, trigger or enhance 
problem behaviours, and try to see if that can be modified.
»  Consider soothing, calming or distracting strategies, such as 
suggesting the person does activities they enjoy (e.g. going 
for a walk, listening to music, engaging in conversation), 
especially when they are feeling agitated.
as people with dementia are at risk of abuse and neglect, 
health-care providers should be vigilant to protect the 
person with dementia, and they should apply any relevant 
local policies in this regard. 
3.5  Intervention for carers
»  Identify psychological distress and psychosocial impact  
on carers. Assess the carer’s needs to ensure necessary 
support and resources for their family life, employment,  
social activities and health.
»  Acknowledge that it can be extremely frustrating and stress-
ful to care for people with dementia. It is important that car-
ers continue to take care of people with dementia, avoiding 
hostility towards, or neglect of, the person. Carers need to be 
encouraged to respect the dignity of the person with demen-
tia, involving them in decisions on their life as far as possible.
»  Provide information to people with dementia, as well as  
family and other informal carers, from the time of diagnosis. 
This must be done sensitively and bearing in mind the wishes 
of the person and carers.
»  Provide training and support in specific skills (like managing 
difficult behaviour) if necessary. To make these interventions 
most effective, elicit the active participation of the carer (for 
example through role-play). 
»  Consider providing practical support, e.g. where feasible, 
home-based respite care. Another family member or suitable 
person can supervise and care for the person with dementia 
(preferably in the usual home setting). This can relieve the 
main caregiver who can then rest or carry out other activities. 
»  Explore whether the person qualifies for any disability benefits 
or other social or financial support. This may be from government 
or non-governmental source or social networks.
»  If feasible, try to address the carer’s psychological strain with 
support, problem-solving counselling, or cognitive-behaviour 
interventions (see Depression and Advanced Psychosocial 
Interventions Module).  » DEp and  » int
»  Assess for and treat moderate-severe depression in carers 
(see Depression Module).  » DEp
3.6 Follow-up
»  At least once every three months, perform a regular  
medical and social care review.
»  at each follow-up, assess:
 –  medical and psychiatric co-morbidities, including visual and 
hearing impairment, pain, continence;
 –  stability or progression of symptoms of dementia, looking 
for any new symptoms and any rapid changes;
 –  ability to participate in activities of daily living, and any new 
needs for care;
 –  safety risks (e.g. driving, financial management,  
medication management, home safety risks from cooking 
or smoking, possibility of wandering, etc.); 
 –  presence and severity of depression;
 –  presence and severity of behavioural and psychological 
symptoms of dementia;
 –  risk of self-harm;
 –  if on any medication: treatment response, side-effects and 
adherence as well as cognitive and target symptoms;
 –  any barriers to participating in treatment;
 –  carer strain and coping, needs for information, training and 
support.
»  Compare current assessment with previous notes, and discuss 
findings with the person and their carer.
»  Determine any new supportive needs of the person and / or 
their carer and facilitate as necessary.
»  Discuss and agree on any changes in the treatment plan.
Intervention Details
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»  For behavioural and psychological symptoms of dementia, 
consider antipsychotic medication such as haloperidol or an 
atypical antipsychotic medications only after a trial of psycho-
social interventions. You may consider these medications if 
symptoms persist and there is imminent risk of harm. 
»  Consult a spECialist  
»  Begin 0.5 mg haloperidol orally, or i.m. if necessary. Avoid i.v. 
haloperidol. Avoid diazepam.
»  “Start low, go slow”, titrate, review the need regularly (at 
least monthly), checking also for extrapyramidal side-effects. 
Use the lowest effective dose.
»  Refer to Psychosis Module for details about antipsychotic 
medication.  » psY 3
 Pharmacological Interventions
Do not consider acetylcholinesterase inhibitors (like 
donepezil, galantamine and rivastigmine) or memantine 
routinely for all cases of dementia. Consider them only in 
settings where specifi c diagnosis of Alzheimer Disease can 
be made AND where adequate support and supervision by 
specialists and monitoring (for side-effects) from carers is 
available.
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Alcohol Use and Alcohol Use Disorders ALC
Conditions resulting from different patterns of alcohol consumption 
include acute alcohol intoxication, harmful alcohol use, the alcohol 
dependence syndrome, and the alcohol withdrawal state. Acute 
intoxication is a transient condition following intake of alcohol 
resulting in disturbances of consciousness, cognition, perception, 
affect or behaviour. Harmful use of alcohol is a pattern of alcohol 
consumption that is causing damage to health. The damage may be 
physical (e.g. liver disease) or mental (e.g. episodes of depressive 
disorder). It is often associated with social consequences (e.g. family 
problems, or problems at work).
Alcohol dependence is a cluster of physiological, behavioural and 
cognitive phenomena in which the use of alcohol takes on a much 
higher priority for a given individual than other behaviours that once 
had greater value. The alcohol withdrawal state refers to a group of 
symptoms that may occur upon cessation of alcohol after its 
prolonged daily use.
wire possition
Alcohol Use and Alcohol Use Disorders ALC 1
»  Assess airway and breathing.
»  Put the person on their side to prevent aspiration 
in case they vomit.
»  Refer to hospital if necessary  or 
observe until effects of alcohol have worn off.
»  If methanol poisoning is suspected, 
refer to hospital  for emergency management.
»  Treat immediately with diazepam. » ALC 3.1
»  Treat in hospital or detoxifi cation centre if available. 
»  If withdrawal is complicated by delirium: » ALC 3.1
 –  Treat the withdrawal with diazepam.
 –  Manage in a safe environment.
 – Keep well hydrated.
 –  If delirium or hallucinations persist despite treatment 
of other withdrawal symptoms, then consider using 
antipsychotics such as haloperidol 2.5 – 5 mg orally up 
to 3 times daily.
»  If withdrawal is complicated by a seizure, treat with 
diazepam in the fi rst instance and do not use anticonvul-
sants to prevent further seizures.
If there is disturbance in 
the level of consciousness, 
cognition, perception, affect 
or behaviour following recent 
consumption of alcohol
Alcohol Intoxication is likely
Is withdrawal likely to be 
SEVERE? Look for:
»  Past episodes of severe 
alcohol withdrawal including 
delirium and seizures
»  Other medical or psychiatric 
problems or benzodiazepine 
dependence
»  Severe withdrawal symptoms 
already present only a few 
hours after stopping drinking
1.  Is the person acutely intoxicated 
with alcohol?
2.  Does the person have features of 
alcohol withdrawal?
Look for:
»  Smell of alcohol on the breath
»  Slurred speech
»  Uninhibited behaviour
Assess:
»  Level of consciousness
»  Cognition and perception
Alcohol withdrawal occurs following cessation of heavy alcohol 
consumption, typically between 6 hours and 6 days after the last drink. 
Look for:
»  Tremor in hands
»  Sweating
»  Vomiting
» Increased pulse and blood pressure
»  Agitation
Ask about:
»  Headache
»  Nausea
»  Anxiety
Assessment and Management Guide » for Emergency Cases
NOTE: Seizures and confusion 
may occur in severe cases.
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Acute Wernicke’s encephalopathy
»  Treat all suspected cases with i.v. or i.m. 
thiamine 100 mg 3 times daily for 3 – 5 days. 
» Refer the person urgently to the hospital. 
Head injury
»  Monitor level of consciousness.
»  Seek surgical opinion.  
Alcohol withdrawal delirium
»  Treat alcohol withdrawal delirium. » ALC 3.1
Is this acute Wernicke’s 
encephalopathy, head injury or 
alcohol-withdrawal delirium?
»  Examine for nystagmus and ataxia 
of Wernicke’s encephalopathy. 
Ophthalmoplegia may occur in severe 
cases. 
»  Examine for signs of head injury such 
as lacerations, or bleeding around 
head or ears.
»  Re-assess for alcohol withdrawal 
delirium
3.  Does the person have acute 
confusion or clouding of consciousness 
with recent history of heavy alcohol 
consumption?
ALC 1
Assessment and Management Guide » for Emergency Cases
Exclude other common causes of 
confusion, such as infections, hypoxia, 
hypoglycaemia, hepatic encephalopathy, 
and cerebrovascular accidents.
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»  State clearly the results of alcohol use assess-
ment and explain the links between this level of 
alcohol use, the person’s health problems, and 
the short-term and long-term risks of continuing 
use at the current level.
»  Ask about other substance use  » DRU 2.1
»  Have a short discussion about the person’s 
reasons for their alcohol use. 
  See Brief Interventions » ALC 2.2 for details
»  State clearly the recommendation to either 
cut down to safer levels or stop using alcohol 
completely and your willingness to help the 
person to do so.
 –  If the person is willing to try to cut down 
or stop using alcohol, then discuss ways of 
achieving this objective. 
 –  If not, communicate confi dently that it is pos-
sible to stop or reduce hazardous or harmful 
alcohol use and encourage the person to 
come back if he or she wants to discuss the 
issue further.
»  Follow up at the next opportunity.
»  Seek specialist advice  as needed for people 
with ongoing harmful use of alcohol who have 
failed to respond to brief interventions.
  If the person is an adolescent, see » ALC 2.6
  If it is a women who is pregnant or breast-
feeding, see » ALC 2.7
If YES
»  Conduct a more detailed history 
to look for harmful alcohol use or 
dependence (see point 2 below 
and » ALC 2.1)
If no alcohol dependence
»  the clinical scenario is
HAZARDOUS USE OF ALCOHOL
or 
HARMFUL USE OF ALCOHOL
1.  Look for a pattern of alcohol 
consumption and alcohol-related harm
»  Ask if the person consumes alcohol. 
If YES
»  Ask if the person consumes alcohol in a way that puts 
them at risk of harm:
Drinking quantity and frequency
 –  Has consumed 5 or more standard drinks (or 60 g alcohol)* 
on any given occasion in the last 12 months 
 –  Drinks on average more than two drinks per day 
 –  Drinks every day of the week
Alcohol Use and Alcohol Use Disorders ALC 1
Assessment and Management Guide
NOTE: Detecting alcohol use disorders in routine care
Hazardous use of alcohol and alcohol use disorders are common. Except 
in areas of very low alcohol consumption, people presenting to the health 
facility should be asked about their alcohol consumption. This may be done 
informally or by the use of a questionnaire such as the WHO-AUDIT, or the 
WHO–ASSIST.
*  A standard drink is a measure of the amount of pure 
alcohol consumed, usually between 8 g and 12 g. If the 
amount of alcohol contained in a standard drink in that 
country is outside these limits, the number of standard 
drinks may need to be adjusted.
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2.  Does the person have alcohol 
dependence?
Conduct a detailed alcohol use history » ALC 2.1
Look for:
»  A strong desire or sense of compulsion to take alcohol
»  Diffi culties in controlling alcohol use in terms of its onset, 
termination or levels of use
»  A physiological withdrawal state when alcohol use has 
ceased or been reduced, as shown by the characteristic 
withdrawal syndrome for alcohol; or use of the same (or 
a closely related) substance with the intention of relieving 
or avoiding withdrawal symptoms
»  Evidence of tolerance, such that increased doses of 
alcohol are required in order to achieve effects originally 
produced by lower doses
»  Progressive neglect of alternative pleasures or interests 
because of alcohol use, increased amount of time 
necessary to obtain or take alcohol or to recover from 
its effects
»  Alcohol use persisting despite clear evidence of overtly 
harmful consequences, such as harm to the liver, depressive 
mood states, or impairment of cognitive functioning
If 3 or more features 
are present:
the clinical scenario is 
ALCOHOL DEPENDENCE
»  State clearly the results of the assessment, and explain both the 
short-term and long-term risks of continuing use at the current level.
»  Have a short discussion about the person’s motivations for their 
alcohol use. See Brief Interventions. » ALC 2.2 
»  Advise complete cessation of alcohol.
»  Advise daily consumption of thiamine 100 mg.
»  If the person is willing to try to stop using alcohol, facilitate alcohol 
cessation. 
 – Determine the appropriate setting to cease alcohol. 
 – Plan the cessation of alcohol. 
 – Arrange detoxifi cation if necessary.
 –  During detoxifi cation, treat withdrawal symptoms with 
diazepam.  » ALC 3.1
»  After detoxifi cation, prevent relapse with medication (naltrexone, 
acamprosate or disulfi ram) , if available. » ALC 3.2
»  Assess and treat any medical or psychiatric co-morbidity, ideally 
after 2 – 3 weeks of abstinence as some problems will resolve 
with abstinence.
»  Consider referral to a self-help group (such as Alcoholics Anonymous), 
or a residential therapeutic community » ALC 2.3
»  DO NOT administer punishment in the name of treatment. 
»  Address housing and employment needs. » ALC 2.4
»  Provide information and support to person, carers and family 
members. » ALC 2.5
»  If available, provide psychosocial interventions such as family 
counselling or therapy, problem-solving counselling or therapy, 
cognitive behavioural therapy, motivational enhancement therapy, 
or contingency management therapy. » INT
»  Consider referral to a specialized treatment facility.
»  Follow up as needed, frequently initially.
»  Seek specialist support as needed.
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2.1  Taking alcohol use history
When asking about alcohol consumption:
»  Ask questions without indicating a preferred answer, and try 
not to display surprise at any responses given. 
»  Ask about the level and pattern of consumption of alcohol, as well 
as any behaviours associated with alcohol use that may risk the 
person’s health and the health of others (i.e., where, when and 
with whom alcohol consumption typically occurs, what triggers 
alcohol consumption, activities when intoxicated, financial implica-
tions, capacity to care for children, and violence towards others).
»  Ask about harms from alcohol, including:
 – accidents, driving while intoxicated
 – relationship problems
 – medical problems such as liver disease / stomach ulcers
 – legal / financial problems
 – sex while intoxicated and that is later regretted or risky 
 – alcohol-related violence including domestic violence
»  Ask about commencement and development of alcohol use in 
relation to other life events, for example, by taking a chrono-
logical history.
»  If there is evidence of hazardous or harmful alcohol use, investi-
gate dependence by asking about the development of toler-
ance, withdrawal symptoms, use in greater amounts or over a 
greater length of time than was intended, continued alcohol 
use in the face of problems related to it, difficulty in stopping or 
cutting down alcohol use, and craving for alcohol use. 
»  Ask about social networks and the person’s alcohol and other 
drug consumption patterns. 
When examining the person, look for:
»  presence of intoxication and withdrawal;
»  evidence of long-term heavy alcohol consumption, such as 
liver disease (swollen liver, peripheral signs of liver injury), 
cerebellar or peripheral nerve damage.
Investigations that should be considered (when possible):  
»  liver enzymes and full blood examination.
2.2  Brief interventions to reduce harmful  
alcohol consumption
»  Examples of ways that the harmful or hazardous use of 
alcohol can be reduced
 – not having alcohol at home; 
 –  not going to pubs or other locations where people  
use alcohol; 
 – asking support from family or friends; 
 –  asking the person to come back with family or friends and 
to discuss a way forward together at the health centre.
»  Talking to people about the reasons they use alcohol
 –  Engage the person in a discussion about their alcohol use in 
a way that he / she is able to talk about both the perceived 
benefits of it and the actual and / or potential harms, taking 
into consideration the things that are most important to that 
person in life.
 –  Steer the discussion towards a balanced evaluation of the 
positive and negative effects of alcohol by challenging over-
stated claims of benefits and bring up some of the negative 
aspects which are perhaps being understated.
 –  Avoid arguing with the person and try to phrase something in 
a different way if it meets resistance – seeking to find under-
standing of the real impact of alcohol in the person’s life as 
much as is possible for the person at that time.
 –  Encourage the person to decide for themselves if they want 
to change their pattern of alcohol use, particularly after 
there has been a balanced discussion of the pros and cons of 
the current pattern of use.
 –  If the person is still not ready to stop or reduce alcohol use, 
then ask the person to come back to discuss further.
2.3 Self-help groups 
»  Consider advising people with alcohol dependence to join a 
self-help group, e.g. Alcoholics Anonymous. Consider facili-
tating initial contact, for example by making the appointment 
and accompanying the person to the first session.
2.4 Address housing and employment needs
»  Where available, work with local agencies and community 
resources to provide supported employment for those who 
need support to return to work or find a job and to enable 
access to local employment (or educational) opportunities, 
based on the person’s needs and skill level.
Intervention Details
ALC 2
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»  Where available, work with local agencies and community 
resources to find supported housing or assisted living 
facilities, as well as independent living facilities, if these are 
needed. Carefully consider the capacity of the person and 
the availability of alcohol or other substances in advising and 
facilitating optimal housing arrangements.
2.5 Supporting families and carers
Discuss with families and carers the impact of alcohol use and 
dependence on themselves and other family members, including 
children. Based on feedback from families:
»  Offer an assessment of their personal, social and mental 
health needs.
»  Provide information and education about alcohol use and 
dependence. 
»  Help to identify sources of stress related to alcohol use; 
explore methods of coping and promote effective coping 
behaviours.
»  Inform them about and help them access support groups 
(e.g. self-help groups for families and carers) and other social 
resources.
2.6 Substance use in adolescence
»  Clarify the confidential nature of the health care discussion, 
including in what circumstances parents or other adults will 
be given information. 
»  Identify the most important underlying issues for the adolescent, 
keeping in mind that adolescents are often not able to 
articulate their problems well. This might mean asking open 
ended questions covering the areas covered by the HEAD 
acronym (Home, Education / Employment / Eating, Activities, 
Drugs and alcohol, Sexuality / Safety / Suicide) and allowing 
sufficient time for the discussion.
 
»  Although they usually present with less severe substance 
abuse problems, young people can present with severe  
dependence. It is just as important to screen adolescents  
for drug and alcohol problems as adults. 
»  Provide parents and the adolescent with information on the 
effects of alcohol and other substances on individual health 
and social functioning.
»  Encourage a change in the adolescent’s environment rather 
than focusing directly on the adolescent as being the problem, 
such as by encouraging participation in school or work and 
activities after school / work that occupy the adolescent’s time, 
and encourage participation in group activities which facilitate 
the adolescent’s skill acquisition and contribution to their 
communities. It is important that adolescents are involved in 
activities which interest them.
»  Encourage parents and / or responsible adults to know where 
the adolescent is, who they are with, what they are doing, 
when they will be home, and to expect the adolescent to be 
accountable for their activities.
»  Encourage parents to set clear expectations (at the same  
time being prepared to negotiate these expectations with  
the adolescent), and to discuss with adolescents the 
consequences of the adolescent’s behaviours and non 
conformity with expectations.
 »  Advise parents to limit their own behaviours which may be 
contributing to their children’s substance use, including the 
purchasing or providing of alcohol or the provision of funds 
which are being spent on substance use, keeping in mind 
the potential influence of their own alcohol and drug use on 
their children.
2.7 Women – Pregnancy and breastfeeding 
»  Advise women who are pregnant or considering becoming 
pregnant to avoid alcohol completely.
»  Advise women that consuming even small amounts of alcohol 
early in pregnancy can harm the developing foetus, and that 
larger amounts of alcohol can result in a syndrome of severe 
developmental problems called Foetal Alcohol Syndrome (FAS).
»  Advise women who are breastfeeding to avoid alcohol  
completely. 
»  Given the benefits of exclusive breastfeeding (particularly in 
the first 6 months), if mothers continue to drink alcohol they 
should be advised to limit their alcohol consumption, and 
to minimise the alcohol content of the breast milk, such as 
by breastfeeding before drinking alcohol and not again until 
after blood levels fall to zero (allowing approximately 2 hours 
for each drink consumed, i.e. 4 hours if TWO drinks are  
consumed), or using expressed breast milk.
 
»  Mothers with harmful substance use and young children 
should be offered what social support services are available, 
including additional post natal visits, parenting training, and 
child care during medical visits. 
Alcohol Use and Alcohol Use Disorders
Intervention Details
ALC 2
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3.1  Management of alcohol withdrawal
»  Be alert for the person at risk of a withdrawal syndrome, for 
example, the person with undiagnosed alcohol dependence 
in the district hospital. 
»  When there is evidence of a withdrawal syndrome develop-
ing (or before withdrawal symptoms develop in the case of 
planned withdrawal), administer diazepam  at an initial 
dose of up to 40 mg daily (i.e., 10 mg four times daily or 
20 mg twice daily) for 3 – 7 days. In people with impaired 
hepatic metabolism (e.g. liver failure, elderly) use a single low 
dose initially (5 – 10 mg) and determine the duration of action 
of this dose before prescribing further doses. 
»  Administer thiamine  100 mg / day orally for 5 days (or longer 
if required) to prevent the development of thiamine-deficiency 
syndromes such as Wernicke’s encephalopathy. Consider other 
vitamin supplementation when indicated.
»  Ensure adequate fluid intake and electrolyte requirements 
are met. Correct potassium and magnesium levels that are 
typically low.
»  Ensure carer support.
»  Provide as quiet and non-stimulating an environment as 
possible, which is well lit in the day time and lit enough at 
night to prevent falls if the person gets up in the night. 
»  When the person has severe alcohol dependence (previous 
history of severe alcohol withdrawal, seizures or delirium) 
or concurrent serious medical or psychiatric disorders or is 
lacking adequate support, CONSULT A SPECIALIST, if 
available.  
»  Consider and treat other medical problems (e.g. Wernicke’s 
encephalopathy, hepatic encephalopathy, gastrointestinal 
bleeding, head injury with or without subdural haematoma). 
Benzodiazepines should not be used in people with hepatic 
encephalopathy or respiratory depression.
WHERE to withdraw from alcohol?
»  Have there been past episodes of severe withdrawal 
symptoms, seizures or delirium?
»  Are there other significant medical or psychiatric problems?
»  Do significant withdrawal features develop within 6 hours of 
the last drink?
»  Has outpatient withdrawal failed?
»  Is the person homeless or without any social support?
  If YES to any of the above then inpatient withdrawal 
is preferable.
Alcohol-withdrawal delirium
»  Treat the person in a low stimulus and safe environment 
where they are unlikely to do themselves harm.
»  Treat underlying alcohol withdrawal with diazepam.  
»  Administer thiamine 100 mg i.v. or i.m. 3 times daily for 
5 days.  
»  Use antipsychotic medication, if necessary, for the 
duration of psychotic symptoms only (e.g. haloperidol 
2.5 – 5 mg orally tds).  
»  Maintain hydration.
»  Avoid restraining the person.
  Always consider other causes of delirium and hallucinations 
(e.g. head injury, hypoglycaemia, infection (most commonly 
pneumonia), hypoxia, hepatic encephalopathy or cerebrovas-
cular accidents).
The dose and duration of diazepam treatment should 
be determined individually, according to the severity 
of withdrawal and the presence of other medical 
disorders. In the hospital setting, diazepam can be 
given more frequently (i.e., hourly) and up to higher 
daily doses (i.e., up to 120 mg daily for the fi rst 3 days) 
if necessary and based on frequent assessment of the 
person. 
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3.2  Relapse-prevention medications after 
withdrawal from alcohol  
 Several medications are useful in the treatment of  
alcohol dependence and increase the likelihood of the 
person maintaining abstinence from alcohol. The principal 
medications are acamprosate, naltrexone and disulfiram. The  
decision to use of any of these medications should be made  
taking into consideration preferences of the person and an  
assessment of benefit versus risk (e.g. is there an excessive risk if 
the medication is administered by non-medically trained health 
workers or if the person has liver disease or is using other drugs). 
All three medications should be avoided, if possible, in women 
who are pregnant or breastfeeding, and in people with significant 
renal or hepatic impairment, although each situation should be 
individually assessed. Where a specialist centre is available, the 
person can be referred there for these and other treatments. 
With these medications, an effective response may include a 
reduction in the quantity and frequency of alcohol consumption, 
if not complete abstinence.
3.2.1  Acamprosate
Acamprosate suppresses the urge to drink alcohol in the 
alcohol-dependent person. It is best started immediately after 
withdrawal from alcohol has been achieved. It is given at a dose 
of 2 tablets (each containing 333 mg acamprosate) three times 
per day, except in people with a body weight of less than 60 kg, 
when the dose is reduced to 2 tablets twice daily. Treatment is 
usually administered for 12 months. Adverse reactions associated 
with acamprosate treatment occur in about 20% of patients and 
include diarrhoea, nausea, vomiting, abdominal pain, pruritus, oc-
casionally maculopapular rash, and, rarely, bullous skin  
reactions. 
3.2.2  Naltrexone 
Naltrexone also suppresses the urge to drink alcohol. It can be 
started after withdrawal from alcohol at a dose of 50 mg daily.  
It is then maintained within the 50 – 100 mg range for 12 
months. Importantly, the person must not have taken any opioid 
drugs for the previous 7 days. The person must be warned that 
naltrexone will block opioid drugs in case they need opioid 
analgesia in the near future. Adverse reactions occur in about 
20% of patients and include nausea, vomiting, abdominal pain, 
anxiety, sleeping difficulties, headache, reduced energy, joint 
and muscle pain. Liver toxicity can occur with higher doses of 
naltrexone and, if feasible, liver function tests should be routinely 
carried out. 
3.2.3  Disulfiram 
The effect of disulfiram is based on the fear of the unpleasant 
and potentially dangerous reaction, which includes facial flush-
ing, nausea, vomiting and fainting, when alcohol is consumed by 
the person taking the medication. The person must be advised 
of its mechanism of action and the nature of the disulfiram-alcohol 
reaction, including the fact that 1 in 15,000 patients treated 
with it die as a result of the reaction (this is low compared with 
the risk of dying from untreated alcohol dependence). Disulfiram 
should be offered to motivated patients for whom medication 
adherence can be monitored by treatment personnel, carers 
or family members, and when health-care providers are aware 
of potential adverse effects, including the disulfiram-alcohol 
reaction. The dose is typically 200 mg daily. Adverse reactions 
include drowsiness, fatigue, nausea, vomiting, reduced libido, 
rarely psychotic reactions, allergic dermatitis, peripheral neuritis 
or hepatic cell damage. Disulfiram is contraindicated in people 
with coronary heart disease, cardiac failure, history of cerebro-
vascular accidents, hypertension, psychosis, severe personality 
disorders or suicide risk. 
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Conditions resulting from different patterns of drug use include 
acute sedative overdose, acute stimulant intoxication or overdose, 
harmful or hazardous drug use, cannabis dependence, opioid 
dependence, stimulant dependence, benzodiazepine dependence, 
and their corresponding withdrawal states. 
Harmful use of drugs is a pattern of drug consumption that is 
causing damage to health. The damage may be physical (as in 
cases of infections related to drug use) or mental (e.g. episodes of 
depressive disorder) and is often associated with damage to social 
functioning (e.g. family problems, legal problems or work-related 
problems). 
Drug dependence is a cluster of physiological, behavioural and 
cognitive phenomena in which drug use takes on a much higher 
priority for a given individual than other behaviours that once had 
greater value. 
The drug withdrawal state refers to group of symptoms occurring 
upon cessation of a drug after its prolonged daily use.
wire possition
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»  Treat airway, breathing and circulation
»  naloxone 0.4 mg subcutaneous, i.m. or i.v. (for opioid 
overdose – but ineffective for other sedative overdose), 
repeat if necessary.
»  Observe for 1 – 2 hours after naloxone administration. 
»  For overdoses due to long acting opioids – transport to 
hospital  for naloxone infusion or ventilatory support.
If unresponsive to naloxone  
»  provide airway and ventilatory support and transport to hospital
»  Give diazepam in titrated doses until the person is calm and lightly 
sedated. 
»  If psychotic symptoms do not respond to benzodiazepines, then 
consider using short-term antipsychotics.
»  DO nOt commence long-term antipsychotics. 
»  Monitor blood pressure, pulse rate, respiratory rate, temperature 
every 2 – 4 hours. 
»  If the person complains of chest pain, if tachyarrhythmias are 
present or if the person becomes violent or unmanageable, transfer 
the person to hospital.  
»  During the post-intoxication phase – be alert for suicidal thoughts 
or actions.
»  Treat with reducing doses of opioids (methadone, buprenorphine) 
or alpha-adrenergic agents (clonidine, lofexidine) using either 
supervised dosing or daily dispensing. 
»  Treat specifi c symptoms as needed (diarrhoea, vomiting, muscle 
pain, insomnia).
» Consider starting opioid agonist maintenance treatment.
» Oral or i.v. rehydration, if necessary.
If 
»  Respiratory rate 
< 10 OR
»  Oxygen saturation 
< 92 %
Cocaine or 
amphetamine-type 
stimulant intoxica-
tion or overdose
Opioid withdrawal
Opioid overdose or other sedative overdose or mixed drug with 
or without alcohol overdose 
» Unresponsive or minimally responsive 
» Slow respiratory rate
» Pinpoint pupils (opioid overdose)
»  History of opioid dependence, recent heavy use ceasing in the last days
» Muscle aches and pains, abdominal cramps, headaches 
» Nausea, vomiting, diarrhoea 
» Dilated pupils
» Raised pulse and blood pressure
» Yawning, runny eyes and nose, pilo-erection (“goosefl esh”) 
» Anxiety, restlessness
Assessment and Management Guide » for Emergency Cases
1.  Is the person suffering from a sedative 
overdose?
3.  Is the person suffering from acute 
opioid withdrawal?
»  Dilated pupils
»  Excited, racing thoughts, disordered thinking, paranoia
»  Recent use of cocaine or other stimulants
»  Raised pulse and blood pressure
» Aggressive, erratic, or violent behaviour
2.  Is the person in a state of acute 
stimulant intoxication or overdose?
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if YeS then assess for 
dependence (see no. 2 below) 
and drug related harm. If the 
person is NOT drug dependent, 
then the clinical scenario is:
HaZaRDOuS DRuG uSe 
or
HaRMFul DRuG uSe
1.  Does the person use illicit or non-
prescribed drugs in a way that risks 
damage to health?
»  Ask about recent drug use. » DRu 2.1
»  Look for drug-related harm.
nOte: Screening questionnaires, such as the WHO–ASSIST, can be 
used to screen for drug use and related problems
nOte: Case ﬁ nding
The prevalence of drug use disorders varies enormously between 
settings. In settings of high levels of drug use, it might be appropriate 
to ask all patients about their drug consumption. This may be done 
informally or by the use of a questionnaire such as the WHO-ASSIST. 
In other settings, ask about drug use when clinical features suggest 
the presence of a drug use disorder. These include unkempt appearance, 
injuries, infections and mental health problems.
DRU 1
»  State clearly the results of substance use assessment and 
explain the links between this level of substance use, the 
person’s health problems, and the short-term and long-term 
risks of continuing use at the current level.
»  Ask about alcohol and other substance use.  » alC 2.1
»  Have a short discussion about the person’s reasons for 
their drug use. 
»  See Brief interventions » DRu 2.2 for details 
»  State clearly the recommendation to stop harmful substance 
use and your willingness to help the person to do so.
 –  If the person is willing to try to cut down or stop drug use, 
then discuss ways of achieving this objective. 
 –  If not, communicate confi dently that it is possible to 
stop or reduce hazardous or harmful substance use and 
encourage the person to come back if he or she wants 
to discuss the issue further.
»  If the person is an adolescent, see the section on 
adolescent substance use.  » alC 2.6
»  If it is a women who is pregnant or breastfeeding , see 
» DRu 2.7
»  Follow up at the next opportunity.
»  Seek specialist advice as needed for people with ongoing 
harmful drug use who have failed to respond to brief 
interventions.  
Assessment and Management Guide
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2. Are there features of 
drug dependence?
» Conduct a detailed drug use assessment. »  DRu 2.1
look for:
»  Strong desire or sense of compulsion to take drugs
»  Diffi culties in controlling drug use in terms of its onset, 
termination or levels of use
»  A physiological withdrawal state when drug use has 
ceased or been reduced, as shown by the characteristic 
drug-withdrawal syndrome; or use of the same (or a 
closely related) substance with the intention of relieving 
or avoiding withdrawal symptoms
»  Evidence of tolerance, such that increased doses of the 
substance are required in order to achieve effects 
originally produced by lower doses
»  Progressive neglect of alternative pleasures or interests 
because of drug use, increased amount of time necessary 
to obtain or take drug or to recover from its effects
»  Drug use persisting, despite clear evidence of overtly 
harmful consequences
If 3 or more features 
are present,
the clinical scenario is:
DRuG DePenDenCe
»  Cannabis or Stimulant Dependence
 –  Provide a more intensive brief intervention (i.e., up to 3 sessions, each lasting up to 45 minutes). » DRu 2.2
 –  Treat withdrawal symptoms. » DRu 3.3
 –  Arrange detoxifi cation service if necessary.
»  Opioid dependence
 –  Assess severity of dependence. » DRu 2.1
 –  In most cases, advise opioid agonist maintenance treatment (also known as opioid-substitution 
therapy, OST). Provide or refer for OST, if available. » DRu 3.1
 –  Arrange planned detoxifi cation if requested. » DRu 3.1
»  Benzodiazepine dependence
 –  Gradual reduction of benzodiazepines with supervised dispensing or more rapid reduction of 
benzodiazepines in an in-patient setting. » DRu 3.2
in all CaSeS
»  Consider referral to self-help groups, and rehabilitation / therapeutic communities. » DRu 2.3
»  Address housing and employment needs. » DRu 2.4
»  Provide information and support to person, carers and family members. » DRu 2.5
»  If available, provide psychosocial interventions, such as family counselling or therapy, problem-solving 
counselling or therapy, cognitive behavioural therapy, motivational enhancement therapy, contingency 
management therapy. » int
» Offer harm reduction strategies for people who inject drugs. » DRu 2.6
»  State clearly the diagnosis and inform about the risks of short-term 
and long-term harm.
»  Explore the person’s reasons for their drug use, using brief 
intervention techniques. » DRu 2.2 
»  Advise the person to stop using the substance completely and 
indicate the intention to support the person in doing so.
»  Ask the person if they are ready to try to stop using the substance.
Drug Use and Drug Use Disorders DRU 1
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2.1 Assessment
Taking a drug use history
When asking about drug consumption:
»  Ask questions about illicit drug use in a non-judgemental 
way, perhaps after asking about tobacco / nicotine, alcohol 
and any traditional drug use that may be relevant. 
»  Ask about the level and pattern of consumption, and any 
behaviours associated with drug use that may risk health and 
the health of others (e.g. drug smoking, drug injection, 
activities when intoxicated, financial implications, capacity to 
care for children, violence toward others).
»  Ask about commencement and development of drug use  
in relation to other life events, for example by taking a 
chronological history.
»  Ask about harms from drug use including:
 – injuries and accidents 
 – driving while drug affected
 – relationship problems
 – drug injection and related risks
 – legal / financial problems
 – sex while intoxicated and that is risky or later regretted 
»  Enquire about dependence by asking about the development 
of tolerance, withdrawal symptoms, use in greater amounts 
or over a greater length of time than was intended, continued 
drug use in the face of problems related to drug use, difficulty 
in stopping or cutting down drug use, and craving for drug 
use.
Things to look for in the examination
»  Signs of injection: Common injection sites are the  
antecubital fossae or groin. The person may demonstrate 
where they have injected drugs. Old injection marks appear 
as skin pigmentation, or thinning of the skin. New injection 
sites are small and usually slightly red and inflamed. In cases  
of dependence on injected drugs (such as heroin), both new 
and old injection sites should be visible.
»  Presence of intoxication and withdrawal: 
 –  Opioid intoxication: drowsiness, being “on the nod”, slow 
speech, small pupils and depressed respiration. 
 –  Opioid withdrawal: anxiety, dilated pupils, abdominal 
cramps, yawning, runny nose, and piloerection 
(“gooseflesh”). 
 –  Benzodiazepines intoxication: sedation, slowed and slurred 
speech, depressed respiration. 
 –  Benzodiazepine withdrawal: anxiety and agitation, muscle 
cramps, abdominal cramps, raised pulse and blood pressure, 
insomnia, and (when severe) seizures and delirium. 
 –  Stimulant intoxication: hyperactivity, rapid speech and 
dilated pupils. 
 –  Stimulant withdrawal: initially fatigue, increased appetite, 
irritability, emotional depression, and anxiety. 
 –  Cannabis intoxication: red conjunctivae, delayed 
responsiveness, and normal pupil size. 
 –  Cannabis withdrawal: mood lability, anxiety and muscle 
cramps (there may not be any observable features).
 
»  Physical appearance and mental state. Physical 
appearance is a useful guide for the capacity to self-care. 
»  Common health complications of injecting drug use: 
There may be evidence of HIV infection and related illnesses, 
hepatitis B or C, injection site infections, or tuberculosis. 
»  Other common health conditions associated with drug 
use: poor dentition, parasitic skin infections (lice, scabies), 
sexually transmitted diseases, malnutrition.
 Investigations which should be considered
»  Urine drug screen: It can be a useful way of verifying a drug 
use history, particularly if the person has something to gain 
by not telling the truth. It should be conducted before 
commencing OST, and the results should be available before 
the third dose (to prevent accidental overdose in people not 
opioid dependent starting OST). A urine dipstick can be used, 
although it is less reliable.
»  Serology for blood-borne viruses (HIV, hepatitis B and C).
»  Tests for sexually transmitted infections (STI).
» Sputum testing (when tuberculosis is suspected).
Intervention Details
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2.2 Brief intervention techniques
Ways to discuss substance use: 
»  Engage the person in a discussion about their substance use 
in a way that he / she is able to talk about both the perceived 
benefits of it and the actual and / or potential harms, taking 
into consideration the things that are most important to that 
person in life.
»  Steer the discussion towards a balanced evaluation of the 
positive and negative effects of the substance by challenging 
overstated claims of benefits and bring up some of the 
negative aspects which are perhaps being understated.
»  Avoid arguing with the person and try to phrase something  
in a different way if it meets resistance – seeking to find 
understanding of the real impact of the substance in the 
person’s life as much as is possible for that person at that 
time.
»  Encourage the person to decide for themselves if they want 
to change their pattern of substance use, particularly after a 
balanced discussion of the pros and cons of the current 
pattern of use.
»  If the person is still not ready to stop or reduce substance use, 
then ask the person to come back to discuss further, perhaps 
with a family member or friend.
2.3  Self-help groups
Consider advising people with drug dependence to join a self- 
help group, e.g. Narcotics Anonymous. Consider facilitating 
initial contact, for example by making the appointment and 
accompanying the person to the first session.
2.4  Address housing and employment needs
»  Where available, work with local agencies and community 
resources to provide supported employment for those who 
need support to return to work or find a job and to enable 
access to local employment (or educational) opportunities, 
based on the person’s needs and skill level.
»  Where available, work with local agencies and community 
resources to find supported housing or assisted living 
facilities, as well as independent living facilities, if these are 
needed. Carefully consider the capacity of the person and  
the availability of alcohol or other substances in advising and 
facilitating optimal housing arrangements.
2.5  Supporting families and carers
Discuss with families and carers the impact of drug use and  
drug use disorders on themselves and other family members, 
including children. Based on feedback from families:
»  Offer an assessment of their personal, social and mental 
health needs.
»  Provide information and education about drug use and drug 
use disorders. 
»  Help to identify sources of stress related to drug use; explore 
methods of coping and promote effective coping behaviours.
»  Inform them about and help them access support groups  
(e.g. self-help groups or families and carers) and other social 
resources.
 Psychosocial Interventions
Intervention Details
70Drug Use and Drug Use Disorders » Intervention Details
2.6 Harm-reduction strategies 
» Advise on the risks of drug injection. 
»  Provide information on less risky injection techniques and the 
importance of using sterile injection equipment. 
»  Give information on how to access needle and syringe 
exchange programs where they exist, or other sources of 
sterile injection equipment. 
»  Encourage and offer testing for blood-borne viral illnesses, 
whenever possible. 
»  Offer treatment for complications of drug use and other 
medical and psychiatric problems, and psychosocial support, 
even if the person does not wish to cease using drugs at this 
time. 
»  Over time, when a relationship has been established, 
intensified efforts should be made to encourage people who 
inject drugs to receive treatment for their drug use disorders.
2.7 Women – pregnancy and breastfeeding 
»  Inquire about the menstrual cycle and inform women that 
drug use can interfere with the menstrual cycle, sometimes 
creating the false impression that pregnancy is not possible.
»  Advise and support women who are pregnant to stop all 
psychoactive drug use. Pregnant opioid dependent women 
should generally be advised to take an opioid agonist 
replacement such as methadone. 
»  Screen babies of mothers with drug use disorders for 
withdrawal symptoms (also known as neonatal abstinence 
syndrome). Neonatal abstinence syndrome due to maternal 
opioid use should be treated with low doses of opioids (such 
as morphine) or barbiturates. 
»  Advise and support breastfeeding mothers not to use any 
psychoactive drugs.
»  Advise and support mothers with substance use disorders to 
breastfeed exclusively for at least the first 6 months, unless 
there is specialist advice not to breastfeed.
»  Mothers with harmful substance use and young children 
should be offered what social support services are available, 
including additional post natal visits, parenting training,  
and child care during medical visits.
 Psychosocial Interventions
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3.1 Managing opioid withdrawal
 Caution is needed before embarking upon withdrawal  
from opioids, especially where there has been injection use. 
Withdrawal results in lowered tolerance to opioids, and if  
there is resumption of opioid use, the person will be at risk  
of overdose. Withdrawal is best undertaken when there is a 
plan for admission to a residential rehabilitation programme. 
Alternatively, the person may be considered for opioid agonist 
maintenance treatment with either methadone or buprenorphine. 
When a decision is made to initiate withdrawal, inform about 
the expected symptoms and duration of the withdrawal process, 
and select one of the following:
»  Buprenorphine Buprenorphine is given sublingually at a dose 
range of 4 – 16 mg per day for 3 to 14 days. Before initiation 
of buprenorphine treatment, it is important to wait until opioid 
withdrawal symptoms and signs have become evident (at least 
8 hours after the last dose of heroin and at least 24 – 48 hours 
after the last dose of methadone) because there is a risk that 
it will precipitate a withdrawal syndrome. Care should be taken 
particularly if the the person is prescribed other sedative drugs.
»  Methadone is given orally at an initial dose of 15 – 20 mg, 
increasing if necessary to 30 mg per day, and then tapering 
off over 3 to 10 days. Care should be taken particularly if  
the person is prescribed other sedative drugs.
»  Clonidine or lofexidine is given at a dose range of 0.1 – 0.15 mg 
3 times daily (according to body weight). Lightheadedness and 
sedation may result. Symptomatic treatment should be given, 
e.g. treat nausea with anti-emetics, pain with simple analgesics, 
and insomnia with light sedatives. Monitor blood pressure 
closely.
3.2 Managing benzodiazepine withdrawal
Elective withdrawal from benzodiazepines utilizes a gradual 
taper in dose over 8 – 12 weeks and with conversion to long-
acting benzodiazepines; in conjunction with psychosocial 
support. 
If severe uncontrolled benzodiazepine withdrawal develops (or 
occurs in an unplanned way on sudden cessation of these 
drugs): COnSult SPeCialiSt  or other available resource 
person regarding starting a high-dose benzodiazepine sedation 
regime and hospitalisation.
   Avoid prescribing benzodiazepines to unknown outpatients.
3.3  Other drug withdrawal (amphetamines, 
cannabis, cocaine)
»  Manage withdrawal symptoms as they emerge, e.g. treat 
nausea with anti-emetics, pain with simple analgesics, insomnia 
with light sedatives.
»  Maintain hydration.
»  Avoid restraining the person.
»  Allow the person to leave the treatment facility if they wish to 
do so.
»  Depressive symptoms may occur after withdrawal or during 
the withdrawal period and the person may have pre-existing 
depression. Be alert to the risk of suicide. 
3.4  Continued treatment and support  
after detoxification
Offer all people continued treatment, support and monitoring 
after successful detoxification, irrespective of the setting in which 
it was delivered. 
3.5  Opioid agonist maintenance treatment 
(also known as opioid substitution  
treatment)
Opioid agonist maintenance requires the presence of 
established and regulated framework (these medications should 
not be prescribed in the absence of such framework). It is 
characterized by the prescription of long-acting opioids, such  
as methadone and buprenorphine, generally on a daily 
supervised basis. There is strong evidence that agonist 
maintenance treatment with methadone and buprenorphine 
effectively reduces illicit drug use, mortality, spread of HIV  
and criminality, and improves physical and mental health and 
social functioning.
Monitoring: Medications used in opioid agonist maintenance 
treatment are open to misuse and diversion; hence, programmes 
use various methods of limiting the risk of diversion, including 
supervised consumption.
 Pharmacotherapy
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Self-harm / Suicide SUI
Suicide is the act of deliberately killing oneself. Self-harm is a 
broader term referring to intentional self-inflicted poisoning or 
injury, which may or may not have a fatal intent or outcome. 
Any person over 10 years of age experiencing any of the following 
conditions should be asked about thoughts or plans of self-harm 
in the last month and about acts of self-harm in the last year:
»  any of the other priority conditions 
(see mhGAP-IG Master Chart);
»  chronic pain;
»  acute emotional distress.
Evaluate thoughts, plans and acts of self-harm during the 
initial evaluation and periodically thereafter as required. 
Attend to the person’s mental state and emotional distress.
Asking about self-harm does NOT provoke 
acts of self-harm. It often reduces anxiety 
associated with thoughts or acts of self-
harm and helps the person feel understood. 
However, try to establish a relationship with 
the person before asking questions about 
self-harm. Ask the person to explain their 
reasons for harming themselves.
wire possition
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»  Medically treat injury or poisoning.  
»  If Acute Pesticide Intoxication, follow Pesticide Intoxication 
Management. » SUI 2.3
»  If medical hospitalization is needed, continue to monitor the person 
closely to prevent suicide.
In all cases:
Place the person in a secure and supportive environment at the health 
facility (do not leave them alone).
» Care for the person with self-harm. » SUI 2.1
»  Offer and activate psychosocial support. » SUI 2.2
»  Consult mental health specialist if available.  
»  Maintain regular contact and follow-up. » SUI 2.4 
If person requires 
urgent medical 
treatment for act of 
self-harm
1.  Has the person attempted a medically 
serious act of self-harm?
Observe for evidence of self-injury
Look for:
»  Signs of poisoning or intoxication
»  Signs / symptoms requiring urgent medical treatment such as:
 –  bleeding from self-inflicted wound
 –  loss of consciousness
 –  extreme lethargy 
Ask about:
»  Recent poisoning or other self-harm
If NO, assess for  
imminent risk of  
self-harm / suicide
Assessment and Management Guide
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»  Take the following precautions:  
 –  Remove means of self-harm.
 –  Create secure and supportive environment; if possible, 
offer separate, quiet room while waiting.
 –  Do not leave the person alone.
 –  Supervise and assign a named staff member or a 
family member to ensure safety.
 –  Attend to mental state and emotional distress.
»  Offer and activate psychosocial support. » SUI 2.2
»  Consult mental health specialist, if available.  
»  Maintain regular contact and follow-up. » SUI 2.4 
»  Offer and activate psychosocial support. » SUI 2.2 
»  Consult mental health specialist, if available.  
»  Maintain regular contact and follow-up. » SUI 2.4
 If there are: 
»  current thoughts or plan to 
commit suicide / self-harm 
OR 
»  history of thoughts or plan 
of self-harm in the past 
month or act of self-harm 
in the past year in a person 
who is now extremely agi-
tated, violent, distressed 
or uncommunicative
There is imminent risk of 
self-harm / suicide.
If there is no imminent risk of 
self-harm / suicide, but history 
of thoughts or plan of 
self-harm in the past month 
or act of self-harm in the 
past year
2.  Is there an imminent risk of 
self-harm / suicide?
Ask person and carer about:
»  Current thoughts or plan to commit suicide or self-harm 
»  History of thoughts or plan of self-harm in the past month 
or act of self-harm in the past year
»  Access to means of self-harm
Look for:
»  Severe emotional distress
»  Hopelessness
»  Extreme agitation
»  Violence
»  Uncommunicative behaviour
»  Social isolation
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3.  Does the person have concurrent  
priority mental, neurological or  
drug use disorders?  
(See mhGAP-IG Master Chart)
4.  Does the person have chronic pain?
5.  Does the person have emotional 
symptoms severe enough to warrant 
clinical management?
»  Depression
»  Alcohol or drug use disorders
»  Bipolar disorder
»  Psychosis
»  Epilepsy
»  Behavioural disorders
»  Difficulty carrying out usual work, school, domestic or social  
activities
»  Marked distress or repeated help-seeking
»  Repeated self-medication for emotional distress or unexplained 
somatic symptoms
If concurrent priority  
conditions
If chronic pain is present
If YES, 
additional clinical management 
of symptoms is warranted
Manage the concurrent conditions (see relevant modules)  
in conjunction with the above actions.
Manage pain and treat any relevant medical disease.
See the module on Other Significant Emotional or  
Medically Unexplained Complaints. » OTH
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2.1  Care for the person with self-harm 
Place the person in a secure and supportive environment at the 
health facility (do not leave them alone). If a person with self-harm 
must wait for treatment, offer an environment that minimizes 
distress, if possible in a separate, quiet room with supervision 
and regular contact with a named staff member or a family 
member to ensure safety.
»  Remove the means of self-harm.
»  Consult a mental health specialist, if available.  
»  If a mental health specialist is not available, mobilize family, 
friends and other concerned individuals or available 
community resources to monitor and support the individual 
during imminent risk period. » SUI 2.2
»  Treat people who have self-harmed with the same care, 
respect and privacy given to other people, and be sensitive to 
likely emotional distress associated with self-harm.
»  Include the carer(s) if the person wants their support during 
assessment and treatment, although the psychosocial 
assessment should usually include a one-to-one interview 
between the person and health worker to help explore 
private concerns or issues.
»  Provide emotional support to relatives / carers if they need it.
»  Ensure continuity of care.
»  Hospitalization in non-psychiatric services of general  
hospitals with the goal of preventing acts of self-harm is not 
recommended. If admission to a general (non-psychiatric) 
hospital for management of medical consequences of an act 
of self-harm is necessary, monitor the person closely to prevent 
subsequent self-harm in the hospital.
»  If prescribing medication:  
 –  use medicines that are the least dangerous in case of  
overdose;
 –  give prescriptions for short duration (e.g. one week at  
a time).
2.2  Offer and activate psychosocial support
Offer psychosocial support
»  Offer support to the person. 
»  Explore reasons and ways to stay alive. 
»  Focus on the person’s positive strengths by getting them to 
talk of how earlier problems have been resolved.
»  Consider problem-solving therapy for treating people with 
acts of self-harm in the last year, if sufficient human resources 
are available. » INT
Activate psychosocial support
»  Mobilize family, friends, concerned individuals and  
other available resources to ensure close monitoring of  
the individual as long as the risk persists. 
»  Advise the person and carer(s) to restrict access to the means 
of self-harm (e.g. pesticides and other toxic substances, 
medication, firearms) while the individual has thoughts, plans 
or acts of self-harm.
»  Optimize social support from available community resources. 
These include informal resources such as relatives, friends, 
acquaintances, colleagues and religious leaders, or formal 
community resources, if available, such as crisis centres and 
local mental health centres.
»  Inform carers and other family members that asking about 
suicide will often reduce the anxiety surrounding the feeling; 
the person may feel relieved and better understood.
»  Carers of people at risk of self-harm often experience severe 
stress. Provide emotional support to relatives / carers if they 
need it.
»  Inform carers that even though they may feel frustrated with 
the person, it is suggested to avoid hostility or severe criticism 
towards the person at risk of self-harm.
 Advice and Treatment
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2.3  Pesticide Intoxication Management
»  If health-care facility has a minimum set of skills and 
resources, then treat using the WHO document Clinical 
Management of Acute Pesticide Intoxication (http://www.
who.int/mental_health/prevention/suicide/pesticides_
intoxication.pdf).
  Otherwise, transfer the person immediately to a facility 
that has the following resources:  
 –  skills and knowledge about how to resuscitate individuals 
and assess for clinical features of pesticide poisoning;
 –  skills and knowledge to manage the airway, in particular to 
intubate and support breathing until a ventilator can be 
attached;
 –  atropine and means for its intravenous (i.v.) administration if 
signs of cholinergic poisoning develop;
 –  diazepam and means for its i.v. administration if the person 
develops seizures.
»  Consider giving activated charcoal if the person is conscious, 
gives informed consent and presents within one hour of the 
poisoning.
»  Forced emesis is not recommended.
»  Oral fluids should not be given.
2.4  Maintain regular contact and follow-up
»  Maintain regular contact (via telephone, home visits, letters 
or contact cards), more frequently initially (e.g. weekly for 
the initial 2 months) and less frequently as the person improves 
(once in 2 – 4 weeks thereafter). Consider maintaining more 
intensive or longer contact if necessary.
»  Follow up for as long as suicide risk persists. At every contact, 
routinely assess suicide thoughts and plans. If risk is imminent, 
go to the subsection Imminent Risk of Self-harm / Suicide in the 
Assessment and Management section of this module. » SUI 1
 Advice and Treatment
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2.5. Prevention of suicide
 Beyond clinical assessment and management of priority 
conditions, district-level health officers and health-care 
providers can take action to prevent suicide, as follows:
»  Restrict access to means of self-harm (such as 
pesticides, fi rearms, high places).
 –  Actively involve the community to find locally feasible 
ways to implement interventions at the population level 
to reduce access to means of suicide. 
 –  Establish collaboration between health and other 
relevant sectors.
»  Develop policies to reduce harmful use of alcohol 
as a component of suicide prevention particularly 
within populations with high prevalence of alcohol use.
»  Assist and encourage the media to follow 
responsible reporting practices of suicide. 
 –  Avoid language which sensationalizes or normalizes 
suicide or presents it as a solution to a problem. 
 –  Avoid pictures and explicit description of the method 
used.
 –  Provide information about where to seek help.
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Other Signifi cant Emotional or Medically Unexplained Complaints OTH
People in the mhGAP-IG category “Other Significant Emotional 
or Medically Unexplained Complaints” have anxiety, depressive 
or medically unexplained somatic symptoms. They do not have 
any of the conditions covered elsewhere in this document 
(except possibly for the condition self-harm). People in this 
category may experience either “normal” distress or a mental 
disorder not covered in the mhGAP-IG (e.g. somatoform dis-
order, mild depression, dysthymia, panic disorder, generalized 
anxiety disorder, post-traumatic stress disorder, acute stress 
reaction, adjustment disorder).
The management of “Other Significant Emotional or Medically 
Unexplained Complaints” by practitioners trained in mhGAP-IG 
excludes psychotropic medications. Nonetheless, a subset 
of people in this category may benefit from medication 
prescribed by a qualified practitioner trained in diagnosis and 
evidence-based treatment of conditions not covered in this 
Intervention Guide.
»  This module should not be considered 
for people who meet the criteria for any 
of the mhGAP priority conditions (except 
for the condition self-harm).
»  This module should only be used after 
explicitly ruling out moderate-severe 
depression (» DEP).
wire possition
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»  Conduct a general medical examination and essential  
investigations
1.  Does the person have moderate- 
severe depression or any other priority 
condition (other than self-harm)?
2.  Does the person have a physical  
condition that fully explains the  
presence of the symptoms?
»  Terminate assessment and go to relevant module. 
»  Terminate assessment. 
»  Initiate relevant medical treatment and follow-up.
In ALL cases:
»  DO NOT prescribe antidepressants or benzodiazepines. 
»  DO NOT manage complaints with injections or other ineffective 
treatments (e.g. vitamins). 
»  Address current psychosocial stressors. » DEP 2.2
»  In adolescents and adults: 
 –  Address inappropriate self-medication. 
 –  Reactivate social networks. » DEP 2.3
 –  Where available, consider one of the following treatments: 
structured physical activity programme, » DEP 2.4 behavioural 
activation, relaxation training, or problem-solving treatment. » INT
»  Follow up. CONsuLT A sPECIALIsT  if no improvement at all or 
if the person (or his / her parents) asks for more intense treatment.
If YEs
If YEs
If NO 
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3.  Are there prominent medically 
unexplained somatic symptoms?
Follow above advice (applicable to ALL cases) plus:
»  Avoid unnecessary medical tests / referrals and do not offer placebo.  
»  Acknowledge that the symptoms are not “imaginary”. 
»  Communicate results of tests / examination, saying that no 
dangerous disease has been identiﬁ ed, but that it is 
nevertheless important to deal with the distressing symptoms. 
»  Ask for the person’s explanations of somatic symptoms.
»  Explain how bodily sensations (stomach ache, muscle tension) 
can be related to experiencing emotions, and ask for potential 
links between the person’s bodily sensations and emotions.
»  Encourage continuation of (or gradual return to) normal activities.
»  Advise the person to re-consult if symptoms worsen.
If YEs
Follow above advice (applicable to ALL cases) plus:
»  In case of bereavement: support culturally appropriate mourning /  
adjustment and reactivate social networks. » DEP 2.3
»  In case of acute distress after recent traumatic events: offer basic 
psychological support (psychological ﬁ rst-aid), i.e., listen without 
pressing the person to talk; assess needs and concerns; ensure 
basic physical needs are met; provide or mobilize social support 
and protect from further harm.
»  DO NOT offer psychological debrieﬁ ng (i.e., do not promote 
ventilation by requesting a person to brieﬂ y but systematically 
recount perceptions, thoughts, and emotional reactions 
experienced during a recent, stressful event). 
If YEs4.  Has the person been recently exposed 
to extreme stressors (losses, traumatic 
events)?
»  Manage both the signiﬁ cant emotional or medically unexplained 
complaints (see above) and the risk of self-harm. » suI 1
If YEs
5.  Have there been (a) thoughts or plans 
of suicide / self-harm during the last 
month or (b) acts of self-harm during 
the last year?
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Advanced Psychosocial Interventions INT
For the purposes of the mhGAP-IG, the term “advanced 
psychosocial intervention” refers to an intervention that takes 
more than a few hours of a health-care provider’s time to 
learn and typically more than a few hours to implement. Such 
interventions can be implemented in non-specialized care 
settings, but only when sufficient human resource time is 
made available.
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The interventions described in this section cover both psycho-
logical and social interventions requiring substantial dedicated 
time. A number of the described interventions are known as 
psychotherapies or psychological treatments. Around the world, 
these treatments tend to be provided by specialists specifically 
trained in them. Nonetheless, they may be offered by trained 
and supervised non-specialized health workers. These psycho-
logical treatments are usually provided on a weekly basis over a 
number of months in either individual or group format.
Some of the interventions, such as cognitive behavioural therapy 
and interpersonal psychotherapy, have successfully been imple-
mented by community health workers in low-income countries as 
part of research programmes that ensured that community health 
workers had the time to learn and implement these interventions 
under supervision. These examples show that these interventions 
can be made available through non-specialized human resources, 
opening-up possibilities for scaling up.
Scaling up care requires investment. Health-system managers 
should aim to allocate sufficient human resources to care for mental, 
neurological and substance use disorders in order to ensure the 
wide availability of the interventions covered in this section.
The remainder of this section provides summary descriptions  
of each of the interventions (in alphabetical order). Within the 
modules, these interventions are marked by the abbreviation 
» INT, indicating that these require a relatively more intensive 
use of human resources. There is a need to develop specific 
protocols and training manuals for implementing these inter-
ventions in non-specialized health-care settings.
Behavioural activation
Behavioural activation, which is also a component of cognitive-
behavioural therapy for depression, is a psychological treatment 
that focuses on activity scheduling to encourage a person to 
stop avoiding activities that are rewarding. The mhGAP-IG 
recommends it as a treatment option for depression (including 
bipolar depression) and other significant emotional or medically 
unexplained complaints. 
Cognitive behavioural therapy (CBT)
Cognitive behavioural therapy (CBT) is based on the idea that 
feelings are affected by thinking and behaviour. People with 
mental disorder tend to have unrealistic distorted thoughts, 
which if unchecked can lead to unhelpful behaviour. CBT typi-
cally has a cognitive component (helping the person develop the 
ability to identify and challenge unrealistic negative thoughts) 
and a behavioural component. CBT is different for different 
mental health problems. The mhGAP-IG recommends it as a 
treatment option for depression (including bipolar depression), 
behavioural disorders, alcohol use disorders or drug use disor-
ders, and also recommends it as a treatment option for psycho-
sis just after the acute phase. 
Contingency management therapy
Contingency management therapy is a structured method of 
rewarding certain desired behaviours, such as attending treat-
ment, behaving appropriately in treatment and avoiding harmful 
substance use. Rewards for desired behaviours are reduced over 
time as the natural rewards become established. The mhGAP-IG 
recommends it as a therapy for people with alcohol use disor-
ders or drug use disorders.
Family counselling or therapy
Family counselling or therapy should include the person if 
feasible. It entails multiple (usually more than six) planned 
sessions over a period of months. It should be delivered to 
individual families or groups of families. It has supportive and 
educational or treatment functions. It often includes negotiated 
problem-solving or crisis management work. The mhGAP-IG 
recommends it as a therapy for people with psychosis, alcohol 
use disorders or drug use disorders.
Interpersonal psychotherapy (IPT)
Interpersonal psychotherapy (IPT) is a psychological treatment 
designed to help a person identify and address problems in their 
relationships with family, friends, partners and other people. The 
mhGAP-IG recommends it as a treatment option for depression, 
including bipolar depression. 
Motivational enhancement therapy
Motivational enhancement therapy is a structured therapy, 
typically lasting four sessions or less, to help people who are 
dependent on substances. It involves an approach to motivate 
change by using the motivational interviewing techniques 
described in the section on brief interventions. » ALC 2.2 The 
mhGAP-IG recommends it as therapy for people with alcohol 
use disorders or drug use disorders.
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Parent skills training for parents of children  
and adolescents with behavioural disorders
Parent skills training for parents of children with behavioural 
disorders involves training focusing on positive parent-child 
interactions and emotional communication, teaching the 
importance of parenting consistency, discouraging harsh 
punishments and requiring the practice of new skills with 
their children during the training. Although the content 
should be culturally sensitive, it should not allow violation 
of children’s basic human rights according to internation-
ally endorsed principles. Providing parent training requires 
that the health-care providers receive training themselves.
Parent skills training for parents of children  
and adolescents with developmental disorders
Parent skills training for parents of children with developmental 
disorders involves using culturally appropriate training material 
relevant to the problem to improve development, functioning 
and participation of the child within families and communities. 
It involves techniques teaching specific social, communicative 
and behavioural skills using behavioural principles (e.g. teaching 
new behaviours by rewarding these behaviours, or addressing 
problem behaviours by carefully analysing triggers of the prob-
lem behaviour) to change contributing environmental factors. 
Parents need to be supported in the application of the training. 
Parents of children with different levels of intellectual disability 
and specific problem behaviours need to develop additional 
skills adapted to the needs of their children. Health-care provid-
ers need additional training to be able to offer parent training.
Problem-solving counselling or therapy
Problem-solving counselling or therapy is a psychological  
treatment involving offering direct and practical support.  
The therapist and person work together to identify and isolate 
key problem areas that might be contributing to the person’s 
mental health problems, to break these down into specific, 
manageable tasks, and to problem-solve and develop coping 
strategies for particular problems. The mhGAP-IG recommends  
it as an adjunct treatment option for depression (including  
bipolar depression) and as a treatment option for alcohol use  
disorders or drug use disorders. It is also recommended for  
self-harm, other significant emotional or medically unexplained  
complaints, or parents of children and adolescents with  
behavioural disorders.
Relaxation training
This intervention involves training the person in techniques such 
as breathing exercises and progressive relaxation to elicit the re-
laxation response. Progressive relaxation teaches how to identify 
and relax specific muscle groups. Usually treatment consists of 
daily relaxation exercises for at least 1 – 2 months. The mhGAP-
IG recommends it as an adjunct treatment option for depression 
(including bipolar depression), and as a treatment option for 
other significant emotional or medically unexplained complaints.
Social skills therapy
Social skills therapy helps rebuild skills and coping in social  
situations to reduce distress in everyday life. It uses role-playing, 
social tasks, encouragement and positive social reinforcement  
to help improve ability in communication and social interactions.  
Skills training can be done with individuals, families and groups.  
Usually treatment consists of 45 to 90 minute sessions once or 
twice per week for an initial 3 months and then monthly later. 
The mhGAP-IG recommends it as a treatment option for people  
with psychosis or behavioural disorder.
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For more information,  
please contact:
Department of Mental Health and 
Substance Abuse
World Health Organization
Avenue Appia 20
CH-1211 Geneva 27
Switzerland
 
Email: mhgap-info@who.int
Website: www.who.int/mental_
health/mhgap
“The mhGAP Intervention Guide signifies a breakthrough for the field of mental health and offers 
hope to people with mental illnesses. It provides clear, user-friendly instructions for diagnosing 
and treating mental illnesses. I cannot imagine a better guide for countries.”
Thomas Bornemann » The Carter Center, USA
“An excellent, practical manual for non-specialist health providers managing mental, neurological 
and substance abuse disorders at the primary and secondary levels of health care, in government 
as well as non-government led systems.”
Allen Foster » President, CBM
“The WHO mhGAP Intervention Guide will open the door to more opportunities for the manage-
ment of disorders that contribute to suffering among individuals and their families worldwide. 
These nuanced algorithms acknowledge that there are no one-size-fits-all interventions; rather, 
evidence-based treatment delivered by non-specialists can and must be tailored to individual 
needs and cultural environments.”
Thomas Insel » Director, National Institute of Mental Health, USA
“A comprehensive and most useful tool, which will contribute significantly to the integration of 
mental health into primary care in several low- and middle-income countries.”
Mario Maj » President, World Psychiatric Association
“The fully evidence based WHO intervention guide will help us extend care to all persons with  
mental illness through the National and District Mental Health Programme in the country.”
K. Sujatha Rao » Secretary, Health & Family Welfare, Government of India
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